Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

13
results for

"Yong-Han Paik"

Article category

Keywords

Publication year

"Yong-Han Paik"

Correspondence

Hepatic neoplasm

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma”
    Su Bin Lim, Hyo Jung Cho
    Clinical and Molecular Hepatology.2024; 30(4): 1009.     CrossRef
  • 6,293 View
  • 56 Download
  • 1 Web of Science
  • Crossref

Original Articles

Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease
Won Sohn, Danbee Kang, Minwoong Kang, Eliseo Guallar, Juhee Cho, Yong-Han Paik
Clin Mol Hepatol 2022;28(4):851-863.
Published online June 3, 2022
DOI: https://doi.org/10.3350/cmh.2022.0037
Background/Aims
This study aimed to investigate the effect of hepatocellular carcinoma (HCC) surveillance using the Korea National Liver Cancer Screening Program on the receipt of curative treatment for HCC and mortality in patients with chronic liver disease.
Methods
This population-based cohort study from the Korean National Health Insurance Service included 2003 to 2015 claims data collected from 1,209,825 patients aged ≥40 years with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis. Patients were divided according to HCC surveillance using ultrasonography and serum alpha-fetoprotein every 6–12 months. The study outcomes were the receipt of curative treatment (surgical resection, radiofrequency ablation, or liver transplantation) and all-cause mortality.
Results
The study population consisted of 1,209,825 patients with chronic hepatitis B, chronic hepatitis C, and liver cirrhosis (median age, 52.0 years; interquartile range, 46–55 years; 683,902 men [56.5%]). The proportion of participants who underwent HCC surveillance was 52.7% (n=657,889). During 10,522,940 person-years of follow-up, 74,433 HCC cases developed, including 36,006 patients who underwent curative treatment. The surveillance group had a significantly higher proportion of curative treatment for HCC than the non-surveillance group after adjusting for confounding factors (adjusted hazard ratio [HR], 5.64; 95% confidence interval [CI], 5.48–5.81). The surveillance group had a significantly lower mortality rate than the non-surveillance group (adjusted HR, 0.56; 95% CI, 0.55–0.56).
Conclusions
HCC surveillance using the national screening program in patients with chronic viral hepatitis or liver cirrhosis provides better opportunity for curative treatment for HCC and improves overall survival.

Citations

Citations to this article as recorded by  Crossref logo
  • Outcomes and Survival of Egyptian Patients With Hepatitis B–Related Hepatocellular Carcinoma: A Multicentre Retrospective Study
    Eman M. F. Barakat, Mohamed Kohla, Ahmed Tawheed, Hend Ibrahim Shousha, Ehab F. Moustafa, Mohamed Said, Hamdy Sayed, Eman Rewisha, Ashraf Omar Abdelaziz, Khaled M. Abd Elaziz, Mohamed Omar Abdelmalek, Hossam Dabees, Amr El Fouly, Eman Elkhateeb, Mohamed M
    Journal of Viral Hepatitis.2026;[Epub]     CrossRef
  • Treatment patterns and clinical outcomes of patients with hepatocellular carcinoma—a cohort study of 1020 patients in Sweden
    Bonnie Bengtsson, Linnea Widman, Per Stål, Hannes Hagström
    Scandinavian Journal of Gastroenterology.2025; 60(10): 1023.     CrossRef
  • Contrasting associations of body mass index and waist circumference with cancer incidence in the elderly: a nationwide population-based study
    Soo Yeon Jang, Minwoong Kang, Eyun Song, Ahreum Jang, Min Jeong Park, Kyung Mook Choi, Sei Hyun Baik, Hye Jin Yoo
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Public health strategies for hepatocellular carcinoma: from risk factors to prevention and control
    Mei-Hsuan Lee
    Journal of Liver Cancer.2025; 25(2): 204.     CrossRef
  • Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study
    Binu V. John, Mark Camardo, Kyle Porter, Paul Z. Elias, Elle Kielar-Grevstad, Seema P. Rego, Neehar D. Parikh, Lewis R. Roberts, Alvin C. Silva, Amit G. Singal, Ju Dong Yang, Paul J. Limburg
    Hepatology Communications.2025;[Epub]     CrossRef
  • PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B
    Ho Soo Chun, George V. Papatheodoridis, Minjong Lee, Hye Ah Lee, Yeong Hwa Kim, Seo Hyun Kim, Yun-Seo Oh, Su Jin Park, Jihye Kim, Han Ah Lee, Hwi Young Kim, Tae Hun Kim, Eileen L. Yoon, Dae Won Jun, Sang Hoon Ahn, Vana Sypsa, Cihan Yurdaydin, Pietro Lampe
    Journal of Hepatology.2024; 80(1): 20.     CrossRef
  • Changes in the ultrasound presentation of hepatocellular carcinoma: a center’s three decades of experience
    Lydia Giannitrapani, Simona Amodeo, Luigi Mirarchi, Antonino Terranova, Aurelio Seidita, Chiara Mozzini, Daniela Cabibi, Giuseppe Brancatelli, Anna Licata, Maurizio Soresi
    Journal of Ultrasound.2024; 27(2): 383.     CrossRef
  • Synthesis of Ag-Loaded ZnCo₂O₄ Hierarchical Nanospheres With Improved Isoprene Sensitivity
    Xueling Wang, Xuping Li, Yanwei Li, Guang Sun, Jianliang Cao, Yan Wang
    IEEE Sensors Journal.2024; 24(11): 18288.     CrossRef
  • Recent Hepatocellular Carcinoma Managements in Korea: Focus on the Updated Guidelines in 2022
    Yuri Cho, Bo Hyun Kim, Young-Suk Lim
    Digestive Disease Interventions.2024; 08(03): 169.     CrossRef
  • Association of physical activity, including amount and maintenance, with the risk of HCC among patients with type 2 diabetes
    Wonkyung Han, Kyungdo Han, Seong Gyu Hwang, Sang Hoon Ahn, Mi Na Kim
    JHEP Reports.2024; 6(10): 101166.     CrossRef
  • Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma
    Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim
    Clinical and Molecular Hepatology.2024; 30(3): 360.     CrossRef
  • Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
    Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi
    Journal of Liver Cancer.2024; 24(2): 274.     CrossRef
  • Correspondence on Editorial regarding “Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease”
    Won Sohn, Yong-Han Paik
    Clinical and Molecular Hepatology.2023; 29(1): 182.     CrossRef
  • Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation
    Sihui Zhang, Chao Wang, Bei Liu, Qing-Bin Lu, Jia Shang, Yihua Zhou, Jidong Jia, Xiaoyuan Xu, Huiying Rao, Bingfeng Han, Tianshuo Zhao, Linyi Chen, Mingzhu Xie, Jiahao Cui, Juan Du, Jing zeng, Ninghua huang, Yaqiong Liu, Lei Zhang, Hui Zhuang, Fuqiang Cui
    The Lancet Regional Health - Western Pacific.2023; 35: 100738.     CrossRef
  • A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
    Hao-dan Mao, Shu-qin Zheng, Su-hua Yang, Ze-yu Huang, Yuan Xue, Min Zhou
    PeerJ.2023; 11: e15014.     CrossRef
  • Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
    Shen-Yung Wang
    Clinical and Molecular Hepatology.2023; 29(2): 349.     CrossRef
  • The clinical management of hepatocellular carcinoma in China: Progress and challenges
    Shan Shan, Jidong Jia
    Clinical and Molecular Hepatology.2023; 29(2): 339.     CrossRef
  • The prime time for management of hepatocellular carcinoma in Hong Kong
    Landon L. Chan, Stephen L. Chan
    Clinical and Molecular Hepatology.2023; 29(2): 345.     CrossRef
  • What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
    Min Kyung Park, Yoon Jun Kim
    Clinical and Molecular Hepatology.2023; 29(2): 332.     CrossRef
  • Clinical practice guideline and real-life practice in hepatocellular carcinoma: A Korean perspective
    Myung Ji Goh, Dong Hyun Sinn, Jong Man Kim, Min Woo Lee, Dong Ho Hyun, Jeong Il Yu, Jung Yong Hong, Moon Seok Choi
    Clinical and Molecular Hepatology.2023; 29(2): 197.     CrossRef
  • Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective
    Tung-Hung Su, Chih-Horng Wu, Tsung-Hao Liu, Cheng-Maw Ho, Chun-Jen Liu
    Clinical and Molecular Hepatology.2023; 29(2): 230.     CrossRef
  • Establishment and application of a survival rate graph model based on biomarkers and imaging indexes after primary hepatocellular carcinoma resection
    Yue Xu, Xiaoqin Yao, Jinmei Li, Guoyuan Zhang, Guangcheng Luo, Qiang Wang
    Cancer Medicine.2023; 12(12): 13329.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
    Liver International.2023; 43(8): 1813.     CrossRef
  • Risk factors associated with late hepatocellular carcinoma detection in patients undergoing regular surveillance
    Sangmi Jang, Young-Joo Jin, Jin-Woo Lee, Dam Kwon, Jung Hwan Yu
    Medicine.2023; 102(32): e34637.     CrossRef
  • Surveillance for hepatocellular carcinoma: It is time to move forward
    Bo Hyun Kim, Yuri Cho, Joong-Won Park
    Clinical and Molecular Hepatology.2022; 28(4): 810.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • 10,069 View
  • 239 Download
  • 25 Web of Science
  • Crossref

Hepatic neoplasm

Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2020;26(4):516-528.
Published online September 11, 2020
DOI: https://doi.org/10.3350/cmh.2020.0016
Background/Aims
Although hepatocellular carcinoma (HCC) is notorious for its high recurrence rate, some patients do not experience recurrence for more than 5 years after resection or radiofrequency ablation for early-stage HCC. For those with five recurrence-free period, the risk of HCC recurrence within the next 5 years remains unknown.
Methods
A total of 1,451 consecutive patients (median, 55 years old; males, 79.0%; hepatitis B virus-related, 79.3%) with good liver function (Child-Pugh class A) diagnosed with early-stage HCC by Barcelona Clinic Liver Cancer Staging and received radiofrequency ablation or resection as an initial treatment between 2005 and 2010 were analyzed.
Results
During a median follow-up period of 8.1 years, 961 patients (66.2%) experienced HCC recurrence. The cumulative recurrence rates increased to 39.7%, 60.3%, and 71.0% at 2, 5, and 10 years, respectively, and did not reach a plateau. Five years after HCC diagnosis, 487 patients were alive without experiencing a recurrence. Among them, during a median of 3.9 additional years of follow-up (range, 0.1–9.0 years), 127 patients (26.1%) experienced recurrence. The next 5-year cumulative recurrence rate (5–10 years from initial diagnosis) was 27.0%. Male sex, higher fibrosis-4 scores, and alpha-fetoprotein levels at 5 years were associated with later HCC recurrence among patients who did not experience recurrence for more than 5 years.
Conclusions
The HCC recurrence rate following 5 recurrence-free years after HCC treatment was high, indicating that HCC patients warrant continued HCC surveillance, even after 5 recurrence-free years.

Citations

Citations to this article as recorded by  Crossref logo
  • Entinostat suppresses hepatocellular carcinoma metastasis by upregulating AZGP1 through histone acetylation
    Weiguo Cai, Xinru Pei, Xiaodie Ye, Yan Zhai, Na Wu, Ziyi Wang, Wei Lu
    Biochemical Pharmacology.2026; : 117718.     CrossRef
  • Cure after surgery for hepato-pancreato-biliary cancers: A systematic review
    Marianna Maspero, Carlo Sposito, Vincenzo Mazzaferro, Giorgio Ercolani, Alessandro Cucchetti
    Digestive and Liver Disease.2025; 57(1): 1.     CrossRef
  • What Is the Optimal Locoregional Approach for Recurrent Hepatocellular Carcinoma?
    Neil B. Newman, Colin M. Court, Alexander A. Parikh
    Journal of Clinical Oncology.2025; 43(9): 1050.     CrossRef
  • Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review
    Edoardogregorio Galli, Giorgio Patelli, Federica Villa, Nicole Gri, Chiara Mazzarelli, Iacopo Mangoni, Cristiano Sgrazzutti, Silvia Ghezzi, Andrea Sartore-Bianchi, Luca Saverio Belli, Luciano De Carlis, Angelo Vanzulli, Salvatore Siena, Katia Bencardino
    Cancer Treatment Reviews.2025; 135: 102908.     CrossRef
  • Extrahepatic Recurrence After Surgical Resection of Hepatocellular Carcinoma Without Intrahepatic Recurrence: A Multi-Institutional Observational Study
    Ga Ram You, Shin Young Park, Su Hyeon Cho, Sung Bum Cho, Yang Seok Koh, Chang Hun Lee, Hoon Gil Jo, Sung Kyu Choi, Jae Hyun Yoon
    Cancers.2025; 17(9): 1417.     CrossRef
  • Mesenchymal circulating tumor cells as prognostic markers in HCC Post-Transplantation: Sirolimus as a potential therapeutic Modulator
    Jinyan Chen, Rongsen Wang, Huigang Li, Jiancai Sun, Ruijie Zhao, Jianyong Zhuo, Zuyuan Lin, Chiyu He, Xingzhu Chen, Jun Li, Leyi Chen, Xudong Yang, Xuyong Wei, Shusen Zheng, Xiao Xu, Di Lu
    European Journal of Surgical Oncology.2025; 51(9): 110147.     CrossRef
  • Predictors of long-term survival outcomes of patients with hepatocellular carcinoma without recurrence at five years after liver resection
    Cheng-Ying Hsieh, Chee-Chien Yong, Yueh-Wei Liu, Wei-Feng Li, Chih-Chi Wang, Yi-Hao Yen, Chih-Yun Lin
    Langenbeck's Archives of Surgery.2025;[Epub]     CrossRef
  • Landscape of T-cell exhaustion heterogeneity and HBV integration in virus-related HCC revealed by whole-exome, transcriptome, and single-cell sequencing
    Soon Kyu Lee, Jinyeong Lim, Joo Yeon Jhun, Jeonghyeon Moon, Hye Seon Kim, Jong Young Choi, Ho Joong Choi, Young Kyoung You, Ji Won Han, Pil Soo Sung, Kwon Yong Tak, Seung Kew Yoon, Woong-Yang Park, Mi-La Cho, Jeong Won Jang
    JHEP Reports.2025; 7(11): 101518.     CrossRef
  • Targeting STAT3 by erianin to overcome sorafenib resistance in hepatocellular carcinoma: Integrated network pharmacology with molecular docking, dynamics simulations, and in vitro validation
    Zixian Liu, Ruoning Qian, Yuanchao Feng, Ruogu Qi, Zhengguang Zhang, Fuqiong Zhou
    Biochemical and Biophysical Research Communications.2025; 778: 152348.     CrossRef
  • Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference
    Makoto Hiraoka, Hayaka Uekusa, Akira Okada, Reiko Inoue, Kayo Ikeda-Kurakawa, Yusuke Otsuka, Daisuke Namiki, Ryuichi Yamamoto, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Satoko Yamaguchi, Takashi Kadowaki
    International Journal of Clinical Oncology.2025; 30(11): 2178.     CrossRef
  • Machine Learning‐Based Model for Predicting Recurrence‐Free Survival After Interventional Therapy in Malnourished Hepatocellular Carcinoma Patients
    Ningning Lu, Chunwang Yuan, Bin Sun, Xiongwei Cui, Wenfeng Gao, Yonghong Zhang
    Cancer Medicine.2025;[Epub]     CrossRef
  • Comparative efficacy of postoperative adjuvant transcatheter arterial chemoembolization and hepatic artery infusion chemotherapy in patients with BCLC stage 0-B hepatocellular carcinoma at high risk of recurrence following radical resection
    Xu Feng, Yupei Ao, Jiarui Liu, Jue Yuan, Zhengrong Shi, Chengjia Tang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography
    Dong Wook Kim, Won Chang, So Yeon Kim, Young-Suk Lim, Jonggi Choi, Jungheum Cho, Jin-Wook Kim, Jai Young Cho, Sun Kyung Jeon, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Kyung-Suk Suh, Kwang-Woong Lee, Dong Ho Lee
    Clinical and Molecular Hepatology.2025; 31(4): 1285.     CrossRef
  • Microvascular Invasion in Hepatocellular Carcinoma (Hcc): Implications and Strategy
    Andrea Celotti, M. Bonafede, G. Baiocchi, M. Tomasoni, F. Petrelli, M. Bonomi, G. Grizzi
    Current Surgery Reports.2025;[Epub]     CrossRef
  • Current Immunotherapy Strategies and Emerging Biomarkers for the Treatment of Hepatocellular Carcinoma
    Audrey Kapelanski-Lamoureux, Anthoula Lazaris, Nicholas Meti, Peter Metrakos
    Cancers.2025; 17(23): 3870.     CrossRef
  • The therapeutic efficacy of radical resection for hepatocellular carcinoma varies markedly by tumor location: a retrospective real-world study
    Xu Feng, Yi-Qiu Wei, Jia-Rui Liu, Zheng-Rong Shi, Kai Chen, Yong-Shuang Lv
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Serum Tumor Necrosis Factor-alpha Concentration and its Prognostic Implication in Hepatocellular Carcinoma
    Vembi Rizky Fatmawati, Ulfa Kholili, Husin Thamrin, Ricky Indra Alfaray
    Biomolecular and Health Science Journal.2025; 8(2): 105.     CrossRef
  • Comparative effectiveness of several adjuvant therapies for patients with hepatocellular carcinoma with high-risk factors for recurrence after hepatectomy: a systematic review and meta-analysis
    Zejin Zhao, Haizhao Yi, Yue Xiao, Zhiyan Li, Jinlong Liu
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Mechanism study of oleanolic acid derivative, K73-03, inducing cell apoptosis in hepatocellular carcinoma
    Jiaqi Wang, Chuchu Ma, Zhongyuan Tang, Zhengwu Sun, Eskandar Qaed, Xinming Chi, Jun Wang, Yazeed Jamalat, Zhaohong Geng, Zeyao Tang, Qiying Yao
    Cancer Cell International.2024;[Epub]     CrossRef
  • Machine learning-based model for predicting tumor recurrence after interventional therapy in HBV-related hepatocellular carcinoma patients with low preoperative platelet-albumin-bilirubin score
    Qi Wang, Shugui Sheng, Yiqi Xiong, Ming Han, Ronghua Jin, Caixia Hu
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Smoking as a Risk Factor for Very Late Recurrence in Surgically Resected Early-Stage Primary Hepatocellular Carcinoma
    Wei-Ru Cho, Chih-Chi Wang, Mu-Jung Tsai, Chih-Che Lin, Yi-Hao Yen, Chien Hung Chen, Yuan-Hung Kuo, Chih-Chien Yao, Chao-Hung Hung, Pao-Yuan Huang, An-Che Liu, Ming-Chao Tsai
    Clinical Medicine Insights: Oncology.2024;[Epub]     CrossRef
  • Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway
    Jie Yao, Haoqiang Wan, Jingmei Zhang, Wanying Shen, Xiaofang Wei, Chenyan Shi, Baoru Ou, Dongyu Liu, Lanlan Ge, Jia Fei, Xiaobin Zeng
    Phytomedicine.2024; 129: 155552.     CrossRef
  • Magnetic resonance elastography as a preoperative assessment for predicting intrahepatic recurrence in patients with hepatocellular carcinoma
    Jeong Hyun Lee, Jeong Ah Hwang, Kyowon Gu, Jaeseung Shin, Seungchul Han, Young Kon Kim
    Magnetic Resonance Imaging.2024; 109: 127.     CrossRef
  • Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis
    Yuhua Wen, Lianghe Lu, Jie Mei, Yihong Ling, Renguo Guan, Wenping Lin, Wei Wei, Rongping Guo
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 665.     CrossRef
  • Bioengineered Organoids Offer New Possibilities for Liver Cancer Studies: A Review of Key Milestones and Challenges
    Abdullah Jabri, Jibran Khan, Bader Taftafa, Mohamed Alsharif, Abdulaziz Mhannayeh, Raja Chinnappan, Alaa Alzhrani, Shadab Kazmi, Mohammad Shabab Mir, Aljohara Waleed Alsaud, Ahmed Yaqinuddin, Abdullah M. Assiri, Khaled AlKattan, Yogesh K. Vashist, Dieter
    Bioengineering.2024; 11(4): 346.     CrossRef
  • Glycemic Burden and Clinical Outcomes of Early Stage Hepatocellular Carcinoma after Curative Treatment
    Hyun Joo Lee, Moon Seok Choi, Byeong Geun Song, Won Seok Kang, Geum Youn Gwak, Myung Ji Goh, Yong Han Paik, Joon Hyeok Lee, Dong Hyun Sinn
    Cancers.2024; 16(15): 2652.     CrossRef
  • TFCP2L1 drives stemness and enhances their resistance to Sorafenib treatment by modulating the NANOG/STAT3 pathway in hepatocellular carcinoma
    Dongbo Qiu, Tiantian Wang, Yi Xiong, Kun Li, Xiusheng Qiu, Yuan Feng, Qinghai Lian, Yunfei Qin, Kunpeng Liu, Qi Zhang, Changchang Jia
    Oncogenesis.2024;[Epub]     CrossRef
  • Stage dependent microbial dynamics in hepatocellular carcinoma and adjacent normal liver tissues
    Hee Eun Jo, Sophallika Khom, Sumi Lee, Su Hyeon Cho, Shin Young Park, Ga Ram You, Hyosin Kim, Nah Ihm Kim, Jae-Ho Jeong, Jae Hyun Yoon, Misun Yun
    Scientific Reports.2024;[Epub]     CrossRef
  • Combining transarterial chemoembolization, radiofrequency ablation, and iodine-125 seed implantation for recurrent hepatocellular carcinoma post-hepatectomy
    Yong Zhong, Li Wang, Weibin Dan, Dan Liang
    Diagnostic and Interventional Radiology.2024;[Epub]     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma
    Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao
    World Journal of Gastrointestinal Oncology.2023; 15(1): 1.     CrossRef
  • Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim
    Clinical and Molecular Hepatology.2023; 29(1): 173.     CrossRef
  • Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment
    Sun Kyung Jeon, Dong Ho Lee, Bo‐Yun Hur, Sae‐Jin Park, Se Woo Kim, Junghoan Park, Kyung‐Suk Suh, Kwang‐Woong Lee, Nam‐Joon Yi, Joon Koo Han
    Journal of Magnetic Resonance Imaging.2023; 58(5): 1375.     CrossRef
  • The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes
    Asanda Koza, Ricky H. Bhogal, Nicos Fotiadis, Vasileios K. Mavroeidis
    Biomedicines.2023; 11(4): 1062.     CrossRef
  • Comparison of different adjuvant therapy regimen efficacies in patients with high risk of recurrence after radical resection of hepatocellular carcinoma
    Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi
    Journal of Cancer Research and Clinical Oncology.2023; 149(12): 10505.     CrossRef
  • Classification of microvascular invasion of hepatocellular carcinoma: correlation with prognosis and magnetic resonance imaging
    Yoon Jung Hwang, Jae Seok Bae, Youngeun Lee, Bo Yun Hur, Dong Ho Lee, Haeryoung Kim
    Clinical and Molecular Hepatology.2023; 29(3): 733.     CrossRef
  • Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Shushan Zhang, Yongquan Huang, Songying Pi, Hui Chen, Feile Ye, Chaoqun Wu, Liujun Li, Qing Ye, Yuhong Lin, Zhongzhen Su
    Journal of Nanobiotechnology.2023;[Epub]     CrossRef
  • Inflammation-related prognostic markers in resected hepatocellular carcinoma
    Fabio Giannone, Nevena Slovic, Patrick Pessaux, Catherine Schuster, Thomas F. Baumert, Joachim Lupberger
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma
    Soon Kyu Lee, Dong Jin Chung, Se Hyun Cho
    Journal of Clinical Medicine.2022; 11(2): 302.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Liver-specific LINC01146, a promising prognostic indicator, inhibits the malignant phenotype of hepatocellular carcinoma cells both in vitro and in vivo
    Xiaoyun Ma, Meile Mo, Chao Tan, Jennifer Hui Juan Tan, Huishen Huang, Bihu Liu, Dongping Huang, Shun Liu, Xiaoyun Zeng, Xiaoqiang Qiu
    Journal of Translational Medicine.2022;[Epub]     CrossRef
  • MicroRNA miR-124-3p suppresses proliferation and epithelial–mesenchymal transition of hepatocellular carcinoma via ARRDC1 (arrestin domain containing 1)
    Qiannan Zhao, Fen Jiang, Hui Zhuang, Yanfeng Chu, Fang Zhang, Chenghong Wang
    Bioengineered.2022; 13(4): 8255.     CrossRef
  • Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV–DNA level < 2000 IU/mL
    Hankil Lee, Sungin Jang, Sang Hoon Ahn, Beom Kyung Kim
    Hepatology International.2022; 16(2): 294.     CrossRef
  • Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area
    Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho
    Clinical and Molecular Hepatology.2022; 28(2): 242.     CrossRef
  • A Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 cm
    Chengming Qu, Qiang Wang, Changfeng Li, Qiao Xie, Ping Cai, Xiaochu Yan, Ernesto Sparrelid, Leida Zhang, Kuansheng Ma, Torkel B. Brismar
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • L-Selenocysteine induced HepG-2 cells apoptosis through reactive oxygen species-mediated signaling pathway
    Kaiying Zhang, Jingyao Su, Danyang Chen, Binger Lin, Yucan Wu, Yibing Wang, Jiapei Lei, Ruilin Zheng, Bing Zhu, Yinghua Li
    Molecular Biology Reports.2022; 49(9): 8381.     CrossRef
  • A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets
    Xinghao Fu, Feihong Ji, Qi He, Xinguang Qiu, Fu Wang
    Journal of Immunology Research.2022; 2022: 1.     CrossRef
  • Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study
    Jae Hyun Yoon, Sung Kyu Choi, Sung Bum Cho, Hee Joon Kim, Yang Seok Ko, Chung Hwan Jun
    World Journal of Gastroenterology.2022; 28(36): 5351.     CrossRef
  • Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
    Tae Hyung Kim, Young Kul Jung, Hyung Joon Yim, Joo Won Baik, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun
    Clinical and Molecular Hepatology.2022; 28(4): 876.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • New Evidence of Oral Branched-Chain Amino Acid Supplementation on the Prognosis of Patients With Advanced Liver Disease
    Hankil Lee, Jeong-Ju Yoo, Sang Hoon Ahn, Beom Kyung Kim
    Clinical and Translational Gastroenterology.2022; 13(12): e00542.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Does Neutrophil to Lymphocyte Ratio Have a Role in Identifying Cytokeratin 19-Expressing Hepatocellular Carcinoma?
    Chao-Wei Lee, Sey-En Lin, Ming-Chin Yu, Hao-Wei Kou, Cheng-Han Lee, Tony Kuo, Kuan-Chieh Lee, Hsin-I Tsai
    Journal of Personalized Medicine.2021; 11(11): 1078.     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • Immunological Markers, Prognostic Factors and Challenges Following Curative Treatments for Hepatocellular Carcinoma
    Soon Kyu Lee, Sung Won Lee, Jeong Won Jang, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
    International Journal of Molecular Sciences.2021; 22(19): 10271.     CrossRef
  • Knockdown of Atg7 suppresses Tumorigenesis in a murine model of liver cancer
    Kyung Joo Cho, Sun Yeong Shin, Hyuk Moon, Beom Kyung Kim, Simon Weonsang Ro
    Translational Oncology.2021; 14(9): 101158.     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • New next-generation microwave thermosphere ablation for small hepatocellular carcinoma
    Hideyuki Tamai, Jumpei Okamura
    Clinical and Molecular Hepatology.2021; 27(4): 564.     CrossRef
  • Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
    Ying Liu, Yuzhu Wang, Xinkun Guo, Yifeng He, Jian Zhou, Qianzhou Lv, Xiaowu Huang, Xiaoyu Li
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • 10,630 View
  • 226 Download
  • 67 Web of Science
  • Crossref

Case Report

Hepatic involvement of systemic disease

A case of Alagille syndrome presenting with chronic cholestasis in an adult
Jihye Kim, Bumhee Yang, Namyoung Paik, Yon Ho Choe, Yong-Han Paik
Clin Mol Hepatol 2017;23(3):260-264.
Published online July 7, 2017
DOI: https://doi.org/10.3350/cmh.2016.0057
Alagille syndrome (AGS) is a complex multisystem disorder that involves mainly the liver, heart, eyes, face, and skeleton. The main associated clinical features are chronic cholestasis due to a paucity of intrahepatic bile ducts, congenital heart disease primarily affecting pulmonary arteries, vertebral abnormalities, ocular embryotoxon, and peculiar facies. The manifestations generally become evident at a pediatric age. AGS is caused by defects in the Notch signaling pathway due to mutations in JAG1 or NOTCH2. It is inherited in an autosomal dominant pattern with a high degree of penetrance, but variable expressivity results in a wide range of clinical features. Here we report on a 31-year-old male patient who presented with elevated serum alkaline phosphatase and gamma-glutamyl transpeptidase, and was diagnosed with AGS associated with the JAG1 mutation after a comprehensive workup.

Citations

Citations to this article as recorded by  Crossref logo
  • Alagille Syndrome: Unraveling the Complexities of Genotype–Phenotype Relationships and Exploring Avenues for Improved Diagnosis and Treatment
    Priya Sharma, Deepti Abbey
    Cell Biology International.2025; 49(5): 435.     CrossRef
  • Management of adults with Alagille syndrome
    Mohammed D. Ayoub, Ahmad A. Bakhsh, Shannon M. Vandriel, Verena Keitel, Binita M. Kamath
    Hepatology International.2023; 17(5): 1098.     CrossRef
  • Alagille Syndrome Nowadays: “One, no-One and One Hundred Thousand”
    M. Arrabito, S. D’Amico, C. Gulizia, L. Marino, G.F. Parisi, M. Papale, S. Manti, S. Leonardi
    International Journal of Pediatrics and Child Health.2022; 10: 30.     CrossRef
  • Alagille syndrome caused by NOTCH2 mutation presented atypical pathological changes
    Yiling ShenTu, Xiaoxiao Mi, Dong Tang, Yanming Jiang, Ling Gao, Xiaojie Ma, Bing Zhou, Wenjun Yang, Junping Shi, Dixiang Lan, Gongying Chen, Ling Gong
    Clinica Chimica Acta.2021; 521: 258.     CrossRef
  • A rare cause of ductopenia: adult onset Alagille syndrome
    Sameera Ansar, Kim Tran, Jason Pinner, Avik Majumdar, Catriona McKenzie
    Pathology.2020; 52(5): 610.     CrossRef
  • Alagille syndrome: an uncommon cause of intrahepatic cholestasis in adults
    Wei Zhang, Xinyan Zhao, Jian Huang, Xiaojuan Ou, Jidong Jia
    Revista Española de Enfermedades Digestivas.2019;[Epub]     CrossRef
  • Persistent cholestasis resulting from duodenal papillary carcinoma in an adolescent male
    Haiyan Fu, Yingchao Li, Gelan Bai, Runkai Yin, Chunlan Yin, Weina Shi, Lili Zhang, Rongpin Li, Ruiqin Zhao
    Medicine.2019; 98(22): e15708.     CrossRef
  • Alagille syndrome mutation update: Comprehensive overview ofJAG1andNOTCH2mutation frequencies and insight into missense variant classification
    Melissa A. Gilbert, Robert C. Bauer, Ramakrishnan Rajagopalan, Christopher M. Grochowski, Grace Chao, Deborah McEldrew, James A. Nassur, Elizabeth B. Rand, Bryan L. Krock, Binita M. Kamath, Ian D. Krantz, David A. Piccoli, Kathleen M. Loomes, Nancy B. Spi
    Human Mutation.2019; 40(12): 2197.     CrossRef
  • Novel JAG1 Deletion Variant in Patient with Atypical Alagille Syndrome
    Emanuele Micaglio, Andreea Alina Andronache, Paola Carrera, Michelle M. Monasky, Emanuela T. Locati, Barbara Pirola, Silvia Presi, Mario Carminati, Maurizio Ferrari, Alessandro Giamberti, Carlo Pappone
    International Journal of Molecular Sciences.2019; 20(24): 6247.     CrossRef
  • 14,318 View
  • 154 Download
  • 10 Web of Science
  • Crossref

Original Articles

Hepatic neoplasm

Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
Won Sohn, Ju-Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min-Ah Woo, Sin-Ho Jung, Yong-Han Paik
Clin Mol Hepatol 2017;23(2):170-178.
Published online May 16, 2017
DOI: https://doi.org/10.3350/cmh.2016.0086
Background/Aims
This study aimed to develop and validate a risk prediction model for the development of hepatocellular carcinoma (HCC) in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B (CHB).
Methods
We investigated 2,061 Korean treatment-naïve patients with CHB treated with entecavir as an initial therapy. A risk score model for HCC development was developed based on multivariable Cox regression model in a single center (n=990) and was validated using the time-dependent area under the receiver operating characteristic curve (AUROC) in three other centers (n=1,071). The difference of HCC development among risk groups (low, intermediate, and high) categorized by risk score was also investigated.
Results
The cumulative incidence rates of HCC at 5 years were 11.2% and 8.9% in the testing and validation cohorts, respectively. HCC-Risk Estimating Score in CHB patients Under Entecavir (HCC-RESCUE) is formulated as (age+15×gender [female=0 / male=1]+23×cirrhosis [absence=0 / presence=1]). The AUROCs at 1 year, 3 years, and 5 years were 0.82, 0.81, and 0.81, respectively, in the validation cohort. A significant difference of HCC development in each risk group was determined by the 5-year HCC risk score in the validation cohort (low risk group, 2.1%; intermediate risk group, 9.3%; high risk group, 41.2%, p<0.001).
Conclusions
The study presents a new risk score model with a good ability to predict HCC development and determine high risk patients for HCC development consisting of readily available clinical factors in treatment-naïve CHB patients receiving entecavir.

Citations

Citations to this article as recorded by  Crossref logo
  • Behaviour‐Based Predictive Scores of Hepatocellular Carcinoma in People With Chronic Hepatitis B (ANRS CO22 HEPATHER)
    Clémence Ramier, Camelia Protopopescu, Vincent Di Beo, Lucia Parlati, Fabienne Marcellin, Fabrice Carrat, Tarik Asselah, Marc Bourlière, Patrizia Carrieri
    Liver International.2025;[Epub]     CrossRef
  • Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues
    Jun Inoue, Shinichiro Minami, Kazumichi Abe, Mami Kida, Hiroaki Haga, Chikara Iino, Hiroshi Numao, Hidekatsu Kuroda, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Takehiro Akahane, Tomoo Kobay
    Journal of Viral Hepatitis.2025;[Epub]     CrossRef
  • A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
    Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response
    Haimei Chen, Jie Zhu, Jinhui Zhou, Ziying Yin, Jun Chen, Sudhakar K. Venkatesh, Meng Yin, Richard L. Ehman, Jin Wang
    European Radiology.2025; 35(12): 8032.     CrossRef
  • Novel blood signature for hepatocellular carcinoma screening
    K.-M. Chueng, K.-N. Kwok, S.J.-L. Lam, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, A.K.-Y. Chan, H.H.-W. Liu, S.K.-K. Ng, L. Sutanto, J.C.K. Yung, H.-L. Leung, P.Y.-M. Woo, H.H.-Y. Yiu, D.C.C. Lam
    ESMO Gastrointestinal Oncology.2025; 9: 100185.     CrossRef
  • Current and new strategies for hepatocellular carcinoma surveillance
    Natchaya Polpichai, Chongkonrat Maneenil, Pojsakorn Danpanichkul, Chitchai Rattananukrom, Ashok Choudhury, Yu Jun Wong, Pimsiri Sripongpun, Suthat Liangpunsakul, Apichat Kaewdech
    Gastroenterology Report.2025;[Epub]     CrossRef
  • Score-based prediction model for female hepatocellular carcinoma surveillance in asymptotic HBsAg carriers: a multicenter cohort study in China
    Mengdi Cao, Maomao Cao, Changfa Xia, Fan Yang, Xinxin Yan, Siyi He, Shaoli Zhang, Yi Teng, Qianru Li, Nuopei Tan, Jiachen Wang, Chunfeng Qu, Wanqing Chen
    Journal of the National Cancer Center.2025; 5(5): 493.     CrossRef
  • Dynamic changes in liver stiffness measurement by 2D shear-wave elastography predict hepatocellular carcinoma in patients with chronic hepatitis B and well-controlled viremia: a retrospective study
    Nana Wang, Yuankai Wu, Mingyue Xiao, Yusheng Jie, Jinfen Wang, Manli Wu, Jiaxin Chen, Liuping Sha, Zhongzhen Su, Yutian Chong, Lili Wu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Liver Stiffness Measurements After Oral Antivirals Effectively Predict the Risk of HCC in Patients With Chronic Hepatitis C
    Yu Rim Lee, Hyun Young Woo, Young Oh. Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Min Kyu Kang, Jeong Eun Song, Byoung Kuk Jang, Changhyeong Lee, Byung Seok Kim, Jae Seok Hwang, Woo Jin Chung, Jeong Heo, Nae‐Yun Heo, Seung Ha Park, Jun Sik Yoon, J
    Journal of Gastroenterology and Hepatology.2025; 40(10): 2568.     CrossRef
  • Early screening for liver cancer must be performed
    Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • A prediction nomogram for hepatitis B virus-associated hepatocellular carcinoma
    Yijin Zhang, Gang Wan, Hongjie Li, Lili Gao, Nan Liu, Ping Gao, Yaping Liu, Xuesong Gao, Xuefei Duan
    Scandinavian Journal of Gastroenterology.2024; 59(1): 70.     CrossRef
  • A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular Carcinoma
    Huapeng Lin, Guanlin Li, Adèle Delamarre, Sang Hoon Ahn, Xinrong Zhang, Beom Kyung Kim, Lilian Yan Liang, Hye Won Lee, Grace Lai-Hung Wong, Pong-Chi Yuen, Henry Lik-Yuen Chan, Stephen Lam Chan, Vincent Wai-Sun Wong, Victor de Lédinghen, Seung Up Kim, Terr
    Clinical Gastroenterology and Hepatology.2024; 22(3): 602.     CrossRef
  • Applicability of Risk Scores to an Indian Cohort of Hepatitis B-Related Hepatocellular Carcinoma Patients
    Gautam Ray
    Journal of Clinical and Experimental Hepatology.2024; 14(4): 101370.     CrossRef
  • Reduced Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Receiving Long-Term Besifovir Therapy
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Sang Hoon Ahn, Won Kim, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Sun Young Yim, Jin Kyung Park, Soon
    Cancers.2024; 16(5): 887.     CrossRef
  • Prognostic significance of dynamic changes in liver stiffness measurement in patients with chronic hepatitis B and compensated advanced chronic liver disease
    Hongsheng Yu, Yinan Huang, Mingkai Li, Hao Jiang, Bilan Yang, Xiaoli Xi, Abdukyamu Smayi, Bin Wu, Yidong Yang
    Journal of Gastroenterology and Hepatology.2024; 39(10): 2169.     CrossRef
  • Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
    Lung-Yi Mak
    Journal of Liver Cancer.2024; 24(2): 145.     CrossRef
  • Risk predictive model for the development of hepatocellular carcinoma before initiating long‐term antiviral therapy in patients with chronic hepatitis B virus infection
    Junjie Chen, Tienan Feng, Qi Xu, Xiaoqi Yu, Yue Han, Demin Yu, Qiming Gong, Yuan Xue, Xinxin Zhang
    Journal of Medical Virology.2024;[Epub]     CrossRef
  • Risk stratification and early detection biomarkers for precision HCC screening
    Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida
    Hepatology.2023; 78(1): 319.     CrossRef
  • Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment
    Jun Li, Xiao-Qin Dong, Li-Hua Cao, Zhan-Qing Zhang, Wei-Feng Zhao, Qing-Hua Shang, Da-Zhi Zhang, An-Lin Ma, Qing Xie, Hong-Lian Gui, Guo Zhang, Ying-Xia Liu, Jia Shang, Shi-Bin Xie, Yi-Qi Liu, Chi Zhang, Gui-Qiang Wang, Hong Zhao
    Frontiers in Cellular and Infection Microbiology.2023;[Epub]     CrossRef
  • HCC prediction models in chronic hepatitis B patients receiving entecavir or tenofovir: a systematic review and meta-analysis
    Xiaolan Xu, Lushun Jiang, Yifan Zeng, Liya Pan, Zhuoqi Lou, Bing Ruan
    Virology Journal.2023;[Epub]     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
    Chih-Lin Lin, Jia-Horng Kao
    Clinical and Molecular Hepatology.2023; 29(3): 605.     CrossRef
  • A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Hwiyoung Kim, Taeyun Park, Soo Young Park, Young Eun Chon, Yeon Seok Seo, Jae Seung Lee, Jun Yong park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Seung Up Kim
    Liver International.2023; 43(8): 1813.     CrossRef
  • Improving prediction of hepatocellular carcinoma in chronic hepatitis B by machine learning: Productive relationship of medicine with computer science
    Terry C. F. Yip, Cihan Yurdaydin
    Liver International.2023; 43(8): 1626.     CrossRef
  • Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States
    Hyun-seok Kim, Xian Yu, Jennifer Kramer, Aaron P. Thrift, Pete Richardson, Yao-Chun Hsu, Avegail Flores, Hashem B. El-Serag, Fasiha Kanwal
    Journal of Hepatology.2022; 76(2): 294.     CrossRef
  • An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B
    Hwi Young Kim, Pietro Lampertico, Joon Yeul Nam, Hyung-Chul Lee, Seung Up Kim, Dong Hyun Sinn, Yeon Seok Seo, Han Ah Lee, Soo Young Park, Young-Suk Lim, Eun Sun Jang, Eileen L. Yoon, Hyoung Su Kim, Sung Eun Kim, Sang Bong Ahn, Jae-Jun Shim, Soung Won Jeon
    Journal of Hepatology.2022; 76(2): 311.     CrossRef
  • An MRI-Based Radiomic Model for Individualized Prediction of Hepatocellular Carcinoma in Patients With Hepatitis B Virus-Related Cirrhosis
    Yichen Wei, Jie Gong, Xin He, Bo Liu, Tiejun Liu, Shuohui Yang, Zhipeng Zhou, Lingyan Liang, Songhua Zhan, Ziqiang Xia, Gaoxiong Duan, Bin Lin, Qiuli Han, Shasha Li, Wei Qin, Perry J. Pickhardt, Demao Deng
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
    Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia
    BMC Cancer.2022;[Epub]     CrossRef
  • Hepatitis B Virus-Associated Hepatocellular Carcinoma
    Giacomo Emanuele Maria Rizzo, Giuseppe Cabibbo, Antonio Craxì
    Viruses.2022; 14(5): 986.     CrossRef
  • External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B
    Thierry Poynard, Jean Marc Lacombe, Olivier Deckmyn, Valentina Peta, Sepideh Akhavan, Fabien Zoulim, Victor de Ledinghen, Didier Samuel, Philippe Mathurin, Vlad Ratziu, Dominique Thabut, Chantal Housset, Hélène Fontaine, Stanislas Pol, Fabrice Carrat
    Gastro Hep Advances.2022; 1(4): 604.     CrossRef
  • The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
    Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee
    Clinical and Molecular Hepatology.2022; 28(3): 351.     CrossRef
  • Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
    Sara M. Tony, Mohamed E. A. Shaaban, Ahmed I. M. Mohamed, Mohamed E. A. Abdelrahim
    Beni-Suef University Journal of Basic and Applied Sciences.2022;[Epub]     CrossRef
  • A Mac-2 Binding Protein Glycosylation Isomer-Based Risk Model Predicts Hepatocellular Carcinoma in HBV-Related Cirrhotic Patients on Antiviral Therapy
    Chien-Hung Chen, Tsung-Hui Hu, Jing-Houng Wang, Hsueh-Chou Lai, Chao-Hung Hung, Sheng-Nan Lu, Cheng-Yuan Peng
    Cancers.2022; 14(20): 5063.     CrossRef
  • Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis
    Jae Lee, Tae Lim, Hye Lee, Seung Kim, Jun Park, Do Kim, Sang Ahn, Hyun Lee, Jung Lee, Ja Kim, In Min, Beom Kim
    Diagnostics.2022; 13(1): 3.     CrossRef
  • Validation of risk prediction scores for hepatocellular carcinoma in patients with chronic hepatitis B treated with entecavir or tenofovir
    Jin Won Chang, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Yu Rim Lee, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Soo Young Park, Seung Up Kim
    Journal of Viral Hepatitis.2021; 28(1): 95.     CrossRef
  • Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
    Pierre Nahon, Erwan Vo Quang, Nathalie Ganne-Carrié
    Journal of Clinical Medicine.2021; 10(2): 353.     CrossRef
  • Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update
    James Lok, Kosh Agarwal
    Viruses.2021; 13(7): 1333.     CrossRef
  • Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?
    Coskun Ozer Demirtas, Maurizia Rossana Brunetto
    World Journal of Gastroenterology.2021; 27(33): 5536.     CrossRef
  • Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients
    Jiang Guo, Xue-Song Gao
    World Journal of Clinical Cases.2021; 9(14): 3238.     CrossRef
  • Validation of the HCC‐RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy
    Fatih Güzelbulut, Pınar Gökçen, Güray Can, Gupse Adalı, Ayça Gökçen Değirmenci Saltürk, Özgür Bahadır, Kamil Özdil, Hamdi Levent Doğanay
    Journal of Viral Hepatitis.2021; 28(5): 826.     CrossRef
  • Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B
    George V. Papatheodoridis, George N. Dalekos, Ramazan Idilman, Vana Sypsa, Florian Van Boemmel, Maria Buti, Jose Luis Calleja, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Margarita Papatheodoridi, Nikolaos Gatselis, Rhea Veelken, Marta Lopez-G
    JHEP Reports.2021; 3(3): 100290.     CrossRef
  • Screening for Hepatocellular Carcinoma in Patients with Hepatitis B
    Yashasavi Sachar, Mayur Brahmania, Renumathy Dhanasekaran, Stephen E. Congly
    Viruses.2021; 13(7): 1318.     CrossRef
  • Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective
    Yao-Chun Hsu, Cheng-Hao Tseng, Yen-Tsung Huang, Hwai-I Yang
    Seminars in Liver Disease.2021; 41(03): 285.     CrossRef
  • Validation of the CAMD Score in Patients With Chronic Hepatitis B Virus Infection Receiving Antiviral Therapy
    Seung Up Kim, Yeon Seok Seo, Han Ah Lee, Mi Na Kim, Eun Hwa Kim, Ha Yan Kim, Yu Rim Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seong Gyu Hwang, Kyu Sung Rim, Soon Ho Um, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Soo
    Clinical Gastroenterology and Hepatology.2020; 18(3): 693.     CrossRef
  • Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B
    Thodoris Voulgaris, Margarita Papatheodoridi, Pietro Lampertico, George V. Papatheodoridis
    Liver International.2020; 40(3): 484.     CrossRef
  • Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
    Xinhui Wang, Xiaoli Liu, Zhibo Dang, Lihua Yu, Yuyong Jiang, Xianbo Wang, Zhiyun Yan
    Gut and Liver.2020; 14(2): 232.     CrossRef
  • Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
    Cheng‐Hao Tseng, Chao‐Ming Tseng, Jia‐Ling Wu, Yao‐Chun Hsu, Hashem B. El-Serag
    Journal of Gastroenterology and Hepatology.2020; 35(10): 1684.     CrossRef
  • Nucleos(t)ide analogues and Hepatitis B virus-related hepatocellular carcinoma: A literature review
    Mohamed A Abd El Aziz, Rodolfo Sacco, Antonio Facciorusso
    Antiviral Chemistry and Chemotherapy.2020; 28: 204020662092133.     CrossRef
  • Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma
    Yong Liao
    Genes & Diseases.2020; 7(3): 291.     CrossRef
  • Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy
    Joon Yeul Nam, Dong Hyun Sinn, Junho Bae, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong
    JHEP Reports.2020; 2(6): 100175.     CrossRef
  • Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine
    George V. Papatheodoridis, Thodoris Voulgaris, Margarita Papatheodoridi, W. Ray Kim
    Hepatology.2020; 72(6): 2197.     CrossRef
  • Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine
    Naoto Fujiwara, Scott L. Friedman, Nicolas Goossens, Yujin Hoshida
    Journal of Hepatology.2018; 68(3): 526.     CrossRef
  • Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B
    Yao-Chun Hsu, Terry Cheuk-Fung Yip, Hsiu J. Ho, Vincent Wai-Sun Wong, Yen-Tsung Huang, Hashem B. El-Serag, Teng-Yu Lee, Ming-Shiang Wu, Jaw-Town Lin, Grace Lai-Hung Wong, Chun-Ying Wu
    Journal of Hepatology.2018; 69(2): 278.     CrossRef
  • Effect of Metabolic Syndrome on the Clinical Outcomes of Chronic Hepatitis B Patients with Nucleos(t)ide Analogues Treatment
    Nam Hee Kim, Yong Kyun Cho, Byung Ik Kim, Hong Joo Kim
    Digestive Diseases and Sciences.2018; 63(10): 2792.     CrossRef
  • Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy
    Ji Hyun Kim, Young Don Kim, Minjong Lee, Baek Gyu Jun, Tae Suk Kim, Ki Tae Suk, Seong Hee Kang, Moon Young Kim, Gab Jin Cheon, Dong Joon Kim, Soon Koo Baik, Dae Hee Choi
    Journal of Hepatology.2018; 69(5): 1066.     CrossRef
  • Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy
    Byeong G. Song, Dong H. Sinn, Sangah Chi, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon S. Choi, Joon H. Lee, Kwang C. Koh, Seung W. Paik
    European Journal of Gastroenterology & Hepatology.2018; 30(12): 1447.     CrossRef
  • Development of a nomogram for screening of hepatitis B virus-associated hepatocellular carcinoma
    Jung Wha Chung, Eun Sun Jang, Jaihwan Kim, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Kyung Ho Lee, Jin-Wook Kim
    Oncotarget.2017; 8(63): 106499.     CrossRef
  • 13,234 View
  • 239 Download
  • 66 Web of Science
  • Crossref

Hepatic neoplasm

The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE
Jung Hee Kim, Dong Hyun Sinn, Sung Wook Shin, Sung Ki Cho, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
Clin Mol Hepatol 2017;23(1):42-50.
Published online March 7, 2017
DOI: https://doi.org/10.3350/cmh.2016.0058
Background/Aims
We investigated the outcomes of early-stage hepatocellular carcinoma (HCC) patients who showed a complete response (CR) to initial transarterial chemoembolization (TACE), with a focus on the role of scheduled TACE repetition.
Methods
A total of 178 patients with early-stage HCC who were initially treated with TACE and showed a CR based on the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria on one month follow-up computed tomography (CT) were analyzed. Among them, 90 patients underwent scheduled repetition of TACE in the absence of viable tumor on CT.
Results
During a median follow-up period of 4.6 years (range: 0.4-8.8 years), mortality was observed in 71 patients (39.9%). The overall recurrence-free and local recurrence-free survival rates at 1 year were 44.4% and 56.2%. In the multivariable model, scheduled repetition of TACE was an independent factor associated with survival (hazard ratio [95% confidence interval]: 0.56 [0.34-0.93], P=0.025). When stratified using Barcelona clinic liver cancer (BCLC) stage, scheduled repetition of TACE was associated with a favorable survival rate in BCLC stage A patients, but not in BCLC 0 patients.
Conclusions
Scheduled repetition of TACE was associated with better survival for early-stage HCC patients showing a CR after initial TACE, especially in BCLC stage A patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
    Jiahao Li, Yingnan Liu, Ruipeng Zheng, Chao Qu, Jiarui Li
    Life Sciences.2024; 342: 122540.     CrossRef
  • Local recurrence following complete radiologic response in patients treated with transarterial chemoembolization for hepatocellular carcinoma
    Shamar Young, Tina Sanghvi, Sandeep Sharma, Cameron Richardson, Nathan Rubin, Masters Richards, Donna D'Souza, Siobhan Flanagan, Jafar Golzarian
    Diagnostic and Interventional Imaging.2022; 103(3): 143.     CrossRef
  • Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients
    Woo Jin Jung, Sangmi Jang, Won Joon Choi, Jaewon Park, Gwang Hyeon Choi, Eun Sun Jang, Sook-Hyang Jeong, Won Seok Choi, Jae Hwan Lee, Chang Jin Yoon, Jin-Wook Kim
    Scientific Reports.2022;[Epub]     CrossRef
  • Research Progress on the Predictive Value of Early Curative Effect after TACE for Hepatocellular Carcinoma
    志祥 刘
    Advances in Clinical Medicine.2022; 12(11): 10342.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Association between Time to Local Tumor Control and Treatment Outcomes Following Repeated Loco-Regional Treatment Session in Patients with Hepatocellular Carcinoma: A Retrospective, Single-Center Study
    Krzysztof Bartnik, Wacław Hołówko, Olgierd Rowiński
    Life.2021; 11(10): 1062.     CrossRef
  • Validation of Pre-/Post-TACE-Predict Models among Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization
    David Sooik Kim, Beom Kyung Kim, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Cancers.2021; 14(1): 67.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Long-Term Efficacy and Safety of Partial Splenic Embolization in Hepatocellular Carcinoma Patients with Thrombocytopenia Who Underwent Transarterial Chemoembolization
    Nam Hee Kim, Hong Joo Kim, Yong Kyun Cho, Hyun Pyo Hong, Byung Ik Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma: a propensity score matching study
    Shintaro Shiba, Kei Shibuya, Hiroyuki Katoh, Takuya Kaminuma, Masaya Miyazaki, Satoru Kakizaki, Ken Shirabe, Tatsuya Ohno, Takashi Nakano
    Radiation Oncology.2019;[Epub]     CrossRef
  • Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
    Yaojun Zhang, Mengping Zhang, Minshan Chen, Jie Mei, Li Xu, Rongping Guo, Xiaojun Lin, Jiaping Li, Zhenwei Peng
    JAMA Network Open.2018; 1(6): e183213.     CrossRef
  • 13,182 View
  • 226 Download
  • 13 Web of Science
  • Crossref

Hepatic neoplasm

Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma
Ju-Yeon Cho, Moon Seok Choi, Gil Sun Lee, Won Sohn, Jemma Ahn, Dong-Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2016;22(4):477-486.
Published online December 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0048
Background/Aims
Radiofrequency ablation (RFA) is one of the most frequently applied curative treatments in patients with a single small hepatocellular carcinoma (HCC). However, the clinical significance of and risk factors for early massive recurrence after RFA—a dreadful event limiting further curative treatment—have not been fully evaluated.
Methods
In total, 438 patients with a single HCC of size ≤3 cm who underwent percutaneous RFA as an initial treatment between 2006 and 2009 were included. Baseline patient characteristics, overall survival, predictive factors, and recurrence after RFA were evaluated. In addition, the incidence, impact on survival, and predictive factors of early massive recurrence, and initial recurrence beyond the Milan criteria within 2 years were also investigated.
Results
During the median follow-up of 68.4 months, recurrent HCC was confirmed in 302 (68.9%) patients, with early massive recurrence in 27 patients (6.2%). The 1-, 3-, and 5-year overall survival rates were 95.4%, 84.7%, and 81.8%, respectively, in patients with no recurrence, 99.6%, 86.4%, and 70.1% in patients with recurrence within the Milan criteria or late recurrence, and 92.6%, 46.5%, and 0.05% in patients with early massive recurrence. Multivariable analysis identified older age, Child-Pugh score B or C, and early massive recurrence as predictive of poor overall survival. A tumor size of ≥2 cm and tumor location adjacent to the colon were independent risk factors predictive of early massive recurrence.
Conclusions
Early massive recurrence is independently predictive of poor overall survival after RFA in patients with a single small HCC. Tumors sized ≥2 cm and located adjacent to the colon appear to be independent risk factors for early massive recurrence.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-Term Analysis of Recurrence Beyond Milan Criteria Following Ablation of Solitary Early-Stage Hepatocellular Carcinoma ≤3 cm in Potentially Transplantable Patients: A Over 10-Year Survival Study
    Shuanggang Chen, Han Qi, Hongtong Tan, Fei Cao, Lin Xie, Tao Huang, Ying Wu, Chunyong Wen, Yujia Wang, Lujun Shen, Weijun Fan
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 205.     CrossRef
  • Investigation into the efficiency and prognostic elements of CT-guided ¹²⁵I particle implantation for liver cancer
    Yuxiao Xia, Quanyu Zhou, Xue Jiang, Wenling Tu, Qian Liu, Liangshan Li, Yuhong Shi
    Cancer Imaging.2025;[Epub]     CrossRef
  • Recurrence patterns and survival outcomes after irreversible electroporation for hepatocellular carcinoma: a 6-year multicenter experience
    Min Xu, Shanyu Yin, Qiyu Zhao, Guo Tian, Jinhua Pan, Gang Dong, Wu Zhang, Tuerganaili Aji, Jiansong Ji, Xinhua Chen, Danxia Xu, Tian’an Jiang
    European Radiology.2025;[Epub]     CrossRef
  • BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update
    Maria Reig, Marco Sanduzzi-Zamparelli, Alejandro Forner, Jordi Rimola, Joana Ferrer-Fàbrega, Marta Burrel, Ángeles Garcia-Criado, Alba Díaz, Neus Llarch, Gemma Iserte, Meritxell Mollà, Robin K. Kelley, Peter R. Galle, Vincenzo Mazzaferro, Riad Salem, Brun
    Journal of Hepatology.2025;[Epub]     CrossRef
  • Prognostic model for predicting recurrence in hepatocellular carcinoma patients with high systemic immune-inflammation index based on machine learning in a multicenter study
    Ningning Lu, Shugui Sheng, Yiqi Xiong, Chuanren Zhao, Wenying Qiao, Xiaoyan Ding, Jinglong Chen, Yonghong Zhang
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients—A Multiparametric Prediction
    Sergio Muñoz-Martínez, Victor Sapena, Ángeles García-Criado, Anna Darnell, Alejandro Forner, Ernest Belmonte, Marco Sanduzzi-Zamparelli, Jordi Rimola, Alexandre Soler, Neus Llarch, Gemma Iserte, Ezequiel Mauro, Carmen Ayuso, Jose Rios, Jordi Bruix, Ramon
    Cancers.2023; 15(13): 3269.     CrossRef
  • Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence
    Aswathy R. Devan, Bhagyalakshmi Nair, Manu Kanjoormana Aryan, Vijayastelar B. Liju, Joel Joy Koshy, Bijo Mathew, Arun Valsan, Hoon Kim, Lekshmi R. Nath
    Cancers.2023; 15(10): 2729.     CrossRef
  • Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis
    Yanzhao Zhou, Kun Yuan, Yi Yang, Xiao Shan, Zemin Ji, Dezheng Zhou, Jingzhong Ouyang, Zhengzheng Wang, Qi Zhang, Jinxue Zhou, Qiang Li
    Academic Radiology.2023; 30: S92.     CrossRef
  • Risk factors for recurrence beyond Milan criteria after radiofrequency ablation in transplantable small hepatocellular carcinoma
    Weike Chu, Ping Li, Xue Wu, Peng Zhang, Hui Zhou, Bin Niu
    Revista Española de Enfermedades Digestivas.2022;[Epub]     CrossRef
  • Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma
    Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim
    Clinical and Molecular Hepatology.2022; 28(2): 207.     CrossRef
  • Percutaneous thermal ablation combined with transcatheter arterial chemoembolization for hepatitis C virus-related hepatocellular carcinoma: Efficacy and survival
    Yu Sun, Honghai Zhang, Jiang Long, Yonghong Zhang, Jiasheng Zheng, Chunwang Yuan
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Non‐transplantable recurrence after percutaneous thermal ablation of ≤3‐cm HCC: Predictors and implications for treatment allocation
    Cecilia Gozzo, Margaux Hermida, Astrid Herrero, Fabrizio Panaro, Christophe Cassinotto, Azhar Meerun Mohamad, Eric Assenat, Chloé Guillot, Carole Allimant, Valentina Schembri, Antonio Basile, Sébastien Dharancy, José Ursic‐Bedoya, Boris Guiu
    Hepatology Communications.2022; 6(10): 2975.     CrossRef
  • Integrated Analysis Revealing the Role Of TET3-Mediated MUC13 Promoter Hypomethylation in Hepatocellular Carcinogenesis
    Ruijiao Kong, Hui Zhang, Yin Jia, Qiuhong Man, Shanrong Liu
    Epigenomics.2022; 14(24): 1579.     CrossRef
  • Risk factors of secondary infection/recurrence after ablation for liver cancers: A systemic review and meta-analysis
    Gang Yin, Nengwei Zhang, AMin BuHe, Wei Yan, Tianxiong Li, Jirun Peng
    Journal of Cancer Research and Therapeutics.2022; 18(5): 1352.     CrossRef
  • Risk Factors, Patterns, and Long-Term Survival of Recurrence After Radiofrequency Ablation With or Without Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jingjun Huang, Wensou Huang, Yongjian Guo, Mingyue Cai, Jingwen Zhou, Liteng Lin, Kangshun Zhu
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Four types of tumor progression after microwave ablation of single hepatocellular carcinoma of ≤5 cm: incidence, risk factors and clinical significance
    Zhimei Huang, Zhixing Guo, Jiayan Ni, Mengxuan Zuo, Tianqi Zhang, Rong Ma, Chao An, Jinhua Huang
    International Journal of Hyperthermia.2021; 38(1): 1164.     CrossRef
  • Radiofrequency ablation with four electrodes as a building block for matrix radiofrequency ablation: Ex vivo liver experiments and finite element method modelling. Influence of electric and activation mode on coagulation size and geometry
    Stefaan Mulier, Ricardo Possebon, Yansheng Jiang, Jacques Jamart, Chong Wang, Yi Miao, Tongfu Yu, Kuirong Jiang, Yuanbo Feng, Guy Marchal, Luc Michel, Yicheng Ni
    Surgical Oncology.2020; 33: 145.     CrossRef
  • Long-term outcome of intraoperative radiofrequency ablation for hepatocellular carcinoma and its efficacy as a primary treatment
    Jongduk Kwon, Kwang-Sik Chun, In-Sang Song, Seok-Hwan Kim, Sunjong Han
    Annals of Hepato-Biliary-Pancreatic Surgery.2020; 24(1): 24.     CrossRef
  • Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients
    Jihye Kim, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
    Clinical and Molecular Hepatology.2020; 26(4): 516.     CrossRef
  • Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
    Hsin-Yeh Chen, Sheng-Nan Lu, Chao-Hung Hung, Jing-Houng Wang, Chien-Hung Chen, Yi-Hao Yen, Yuan-Hung Kuo, Kwong-Ming Kee, Tatsuo Kanda
    PLOS ONE.2020; 15(11): e0242113.     CrossRef
  • Feasibility, efficacy, and safety of percutaneous MR‐guided ablation of small (≤12 mm) hepatic malignancies
    Jakob Weiss, Rüdiger Hoffmann, Hansjoerg Rempp, David‐Emanuel Keβler, Philippe L. Pereira, Konstantin Nikolaou, Stephan Clasen
    Journal of Magnetic Resonance Imaging.2019; 49(2): 374.     CrossRef
  • Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization
    Min Young Baek, Jeong-Ju Yoo, Soung Won Jeong, Jae Young Jang, Yong Kwon Kim, Shin Ok Jeong, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim, Yong Jae Kim, Su Yeon Park
    The Korean Journal of Internal Medicine.2019; 34(6): 1223.     CrossRef
  • Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients
    Adam Doyle, Andre Gorgen, Hala Muaddi, Aloysious D. Aravinthan, Assaf Issachar, Oleg Mironov, Wei Zhang, John Kachura, Robert Beecroft, Sean P. Cleary, Anand Ghanekar, Paul D. Greig, Ian D. McGilvray, Markus Selzner, Mark S. Cattral, David R. Grant, Lesli
    Journal of Hepatology.2019; 70(5): 866.     CrossRef
  • Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma
    Matteo Canale, Paola Ulivi, Francesco Giuseppe Foschi, Emanuela Scarpi, Serena De Matteis, Gabriele Donati, Giorgio Ercolani, Mario Scartozzi, Luca Faloppi, Alessandro Passardi, Emiliano Tamburini, Martina Valgiusti, Giorgia Marisi, Giovanni Luca Frassine
    Critical Reviews in Oncology/Hematology.2018; 129: 44.     CrossRef
  • A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma
    Yao Liu, Le Sun, Fangyuan Gao, Xue Yang, Yuxin Li, Qun Zhang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Ying Feng, Yuyong Jiang, Xianbo Wang
    Medicine.2018; 97(49): e13536.     CrossRef
  • Traitement ablatif pour cancer du rein : modalités d’évaluation pré-, per-, post-intervention et prise en charge adaptée
    J. Garnon, T. Tricard, R.L. Cazzato, X. Cathelineau, A. Gangi, H. Lang
    Progrès en Urologie.2017; 27(15): 971.     CrossRef
  • Editorial: rifaximin in cirrhosis—is this what we've been waiting for? Authors’ reply
    S. H. Kang, Y. B. Lee, J.‐H. Lee
    Alimentary Pharmacology & Therapeutics.2017; 46(10): 1017.     CrossRef
  • 12,378 View
  • 168 Download
  • 28 Web of Science
  • Crossref

Hepatic neoplasm

Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma
Jun Young Kim, Dong Hyun Sinn, Geum-Youn Gwak, Gyu-Seong Choi, Aldosri Meshal Saleh, Jae-Won Joh, Sung Ki Cho, Sung Wook Shin, Keumhee Chough Carriere, Joong Hyun Ahn, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Clin Mol Hepatol 2016;22(2):250-258.
Published online June 25, 2016
DOI: https://doi.org/10.3350/cmh.2016.0015
Background/Aims
Several studies have suggested that surgical resection (SR) can provide a survival benefit over transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) at the intermediate stage according to the Barcelona Clinic Liver Cancer (BCLC) staging system. However, the criteria for SR remain to be determined. This study compared the long-term outcome of intermediate-stage HCC patients treated by either TACE or SR as a primary treatment modality, with the aim of identifying the patient subgroup that gained a survival benefit by either modality.
Methods
In total, 277 BCLC intermediate-stage HCC patients treated by either TACE (N=225) or SR (N=52) were analyzed.
Results
The overall median survival time was significantly better for SR than TACE (61 vs. 30 months, P=0.002). Decisiontree analysis divided patients into seven nodes based on tumor size and number, serum alpha-fetoprotein (AFP) level, and Child-Pugh score, and these were then simplified into four subgroups (B1–B4) based on similarities in the overall hazard rate. SR provided a significant survival benefit in subgroup B2, characterized by ‘oligo’ (2–4) nodules of intermediate size (5–10 cm) when the AFP levels was <400 ng/ml, or ‘oligo’ (2–4) nodules of small to intermediate size (<10 cm) plus a Child-Pugh score of 5 when the AFP level was ≥400 ng/mL (median survival 73 vs. 28 months for SR vs. TACE respectively; P=0.014). The survival rate did not differ significantly between SR and TACE in the other subgroups (B1 and B3).
Conclusions
SR provided a survival benefit over TACE in intermediate-stage HCC, especially for patients meeting certain criteria. Re-establishing the criteria for optimal treatment modalities in this stage of HCC is needed to improve survival rates.

Citations

Citations to this article as recorded by  Crossref logo
  • Long-term results of surgical treatment in patients with intermediate stage (BCLC B) hepatocellular carcinoma: a single-center retrospective study
    B. I. Sakibov, D. V. Podluzhnyi, Yu. I. Patyutko, O. A. Egenov, N. E. Kudashkin
    Surgery and Oncology.2025; 15(2): 62.     CrossRef
  • Efficacy of therapies for intermediate-stage hepatocellular carcinoma: systematic review and network meta-analysis
    Shaoqi Zong, Yifan Yang, Zifei Yin, Lanyun Feng, Kun Wang, Hao Chen, Zhen Chen, Zhiqiang Meng, Yongqiang Hua
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Efficacy of postoperative adjuvant hepatic artery infusion chemotherapy for hepatocellular carcinoma in microvascular invasion: a propensity-matched score
    Xu Feng, Xinhua Wu, Kai Chen, Yupei Ao, Zhengrong Shi, Yixuan Gong
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • Conversion Resection or Direct Resection for Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicentre Study
    Ying Zhou, Haiqing Wang, Jiayi Wu, Junyi Shen, Ji Ma, Qiu Li, Weixia Chen, Wusheng Lu, Xielin Feng, Maolin Yan, Tianfu Wen, Xiaoyun Zhang
    Liver Cancer.2025; : 1.     CrossRef
  • Identification of patients with favorable prognosis after resection in intermediate-stage-hepatocellular carcinoma
    Han Ah Lee, Minjong Lee, Jeong-Ju Yoo, Ho Soo Chun, Yewan Park, Hwi Young Kim, Tae Hun Kim, Yeon Seok Seo, Dong Hyun Sinn
    International Journal of Surgery.2024; 110(2): 1008.     CrossRef
  • Application of the Left Lateral Decubitus Position in Laparoscopic Right Posterior Lobectomy
    Dong-Fang Huang, Jian-Bo Xu, Ye-Mu Du, Ye-Bo Wang, Ding-Hua Zhou
    Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2024; 34(2): 178.     CrossRef
  • The role of resection in hepatocellular carcinoma BCLC stage B: A multi-institutional patient-level meta-analysis and systematic review
    Victor Lopez-Lopez, Fabian Kalt, Jian-Hong Zhong, Cristiano Guidetti, Paolo Magistri, Fabrizio Di Benedetto, Arndt Weinmann, Jens Mittler, Hauke Lang, Rohini Sharma, Mathew Vithayathil, Samir Tariq, Patricia Sánchez-Velázquez, Gianluca Rompianesi, Roberto
    Langenbeck's Archives of Surgery.2024;[Epub]     CrossRef
  • Prognostic performance of Hong Kong Liver Cancer with Barcelona Clinic Liver Cancer staging systems in hepatocellular carcinoma
    Mohamed Kohla, Reham Ashour, Hossam Taha, Osama El-Abd, Maher Osman, Mai Abozeid, Sally Waheed ELKhadry
    BMC Gastroenterology.2024;[Epub]     CrossRef
  • Intermediate hepatocellular carcinoma: new horizons and prospects for our patients
    Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Foti, Silvia Camera, Francesco Vitiello, Elisabeth Amadeo, Francesco De Cobelli, Luca Aldrighetti, Margherita Rimini, Andrea Casadei-Gardini
    Expert Review of Gastroenterology & Hepatology.2024; 18(10): 661.     CrossRef
  • Surgical resection for large hepatocellular carcinoma and those beyond BCLC: systematic review with proposed management algorithm
    Saneya Pandrowala, Shraddha Patkar, Mahesh Goel, Darius Mirza, S. K. Mathur
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
    Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
    International Journal of Surgery.2023; 109(5): 1439.     CrossRef
  • Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospecti
    Ko Oshita, Tsuyoshi Kobayashi, Yosuke Namba, Sotaro Fukuhara, Keiso Matsubara, Daisuke Takei, Ryosuke Nakano, Wataru Okamoto, Hiroshi Sakai, Naoki Tanimine, Takashi Nakahara, Shintaro Kuroda, Hiroyuki Tahara, Masahiro Ohira, Tomokazu Kawaoka, Kentaro Ide,
    BMJ Open.2023; 13(10): e073797.     CrossRef
  • A retrospective study of transarterial chemoembolization (TACE) combined with lenvatinib compared with TACE monotherapy for BCLC B2 stage hepatocellular carcinoma
    Junning Liu, Shu Yan, Guangnian Zhang, Linfeng Yang, Song Wei, Pengsheng Yi
    Oncology Letters.2023;[Epub]     CrossRef
  • Novel predictive nomograms based on aspartate aminotransferase‑to‑platelet ratio index for hepatocellular carcinoma with post‑operative adjuvant transarterial chemoembolization
    Qinghua Shu, Nannan Zhang, Jianbo Han, Xiaopeng Yan, Bowen Sha, Liang Zhao, Yongxiang Yi, Yufeng Zhang
    Oncology Letters.2023;[Epub]     CrossRef
  • Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma
    Gianluca Cassese, Ho-Seong Han, Jai Young Cho, Hae-Won Lee, Boram Lee, Roberto Ivan Troisi
    Cancers.2022; 14(23): 5997.     CrossRef
  • The Clinical Value of Postoperative Transarterial Chemoembolization for Resectable Patients with Intermediate Hepatocellular Carcinoma After Radical Hepatectomy: a Propensity Score-Matching Study
    Lei Wang, Chunhong Xiao, Ren Wang, Jingbo Chen, Weiping Zhou, Jingfeng Liu, Nanping Lin, Kongying Lin
    Journal of Gastrointestinal Surgery.2021; 25(5): 1172.     CrossRef
  • Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study
    Hye Kyung Hyun, Eun Ju Cho, Soo Young Park, Young Mi Hong, Soon Sun Kim, Hwi Young Kim, Nae-Yun Heo, Jung Gil Park, Dong Hyun Sinn, Wonseok Kang, Song Won Jeong, Myeong Jun Song, Hana Park, Danbi Lee, Yong Sun Lee, Sung Bum Cho, Chan Sik An, Hyung Jin Rhe
    Digestive Diseases and Sciences.2021; 66(7): 2427.     CrossRef
  • Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma
    Xiang-Ke Niu, Xiao-Feng He
    World Journal of Gastroenterology.2021; 27(2): 189.     CrossRef
  • Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma
    Jae Seung Lee, Young Eun Chon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Wonseok Kang, Moon Seok Choi, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Hwi Young Kim, Tae Hun Kim, Kwon Yoo,
    Yonsei Medical Journal.2021; 62(1): 12.     CrossRef
  • Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
    Yuna Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Current Oncology.2021; 28(1): 965.     CrossRef
  • Prediction of Patient Survival Following Hepatic Resection in Early-Stage Hepatocellular Carcinoma with Indexed Ratios of Aspartate Aminotransferase to Platelets: A Retrospective Cohort Study
    Jian Huang, Yun Yang, Yong Xia, Fu-Chen Liu, Lei Liu, Peng Zhu, Sheng-Xian Yuan, Fang-Ming Gu, Si-Yuan Fu, Wei-Ping Zhou, Hui Liu, Bei-Ge Jiang, Ze-Ya Pan
    Cancer Management and Research.2021; Volume 13: 1733.     CrossRef
  • Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
    Asahiro Morishita, Joji Tani, Takako Nomura, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Tingting Shi, Hiroki Yamana, Takanori Matsui, Tadayuki Takata, Takayuki Sanomura, Yoshihiro Nishiyama, Takashi Himoto, Tetsu Tomonari, Akio Mo
    Cancers.2021; 13(18): 4605.     CrossRef
  • An observational study on long‐term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate
    Tae Seop Lim, Jae Seung Lee, Beom Kyung Kim, Hye Won Lee, Mi Young Jeon, Seung Up Kim, Jun Yong Park, Do Young Kim, Kwang‐Hyub Han, Sang Hoon Ahn
    Journal of Viral Hepatitis.2020; 27(3): 316.     CrossRef
  • Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review
    Biao Yang, Jie Liang, ZiYu Qu, FangYun Yang, ZhengYin Liao, HongFeng Gou, Gianfranco D. Alpini
    PLOS ONE.2020; 15(2): e0227475.     CrossRef
  • Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B
    Jeong-Ju Yoo, Su Jong Yu, Bora Lee, Eun Ju Cho, Jeong-Hoon Lee, Sang Gyune Kim, Yoon Jun Kim, Young Seok Kim, Jung-Hwan Yoon
    Gut and Liver.2020; 14(3): 377.     CrossRef
  • Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study
    Mi Young Jeon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Eun Ju Cho, Seung Up Kim
    Gut and Liver.2020; 14(4): 477.     CrossRef
  • Comparison of Transcatheter Arterial Chemoembolization-Radiofrequency Ablation and Transcatheter Arterial Chemoembolization Alone for Advanced Hepatocellular Carcinoma with Macrovascular Invasion Using Propensity Score Analysis: A Retrospective Cohort Stu
    Yao Liu, Yuxin Li, Fangyuan Gao, Qun Zhang, Xue Yang, Bingbing Zhu, Shuaishuai Niu, Yunyi Huang, Ying Hu, Wei Li, Xianbo Wang
    Journal of Oncology.2020; 2020: 1.     CrossRef
  • Comparison of outcome between liver resection, radiofrequency ablation, and transarterial therapy for multiple small hepatocellular carcinoma within the Milan criteria
    Joo Hyun Oh, Dong Hyun Sinn, Gyu-Seong Choi, Jong Man Kim, Jae-Won Joh, Tae Wook Kang, Dongho Hyun, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Moon Seok Choi
    Annals of Surgical Treatment and Research.2020; 99(4): 238.     CrossRef
  • Is Transarterial Chemoembolization Only Treatment Option in Patients with Intermediate Stage of Hepatocellular Carcinoma?: in Perspectives of Surgery
    Ji Young Lim, Minjong Lee, Tae Hun Kim
    Journal of Liver Cancer.2020; 20(2): 113.     CrossRef
  • A Five‐Gene Signature for Recurrence Prediction of Hepatocellular Carcinoma Patients
    Zeyu Wang, Ningning Zhang, Jiayu Lv, Cuihua Ma, Jie Gu, Yawei Du, Yibo Qiu, Zhiguang Zhang, Man Li, Yong Jiang, Jianqiu Zhao, Huiqin Du, Zhiwei Zhang, Wei Lu, Yan Zhang, Luca Miele
    BioMed Research International.2020;[Epub]     CrossRef
  • Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma
    Qunfang Zhou, Fei Tuo, Ruixia Li, Xiaohui Wang, Juncheng Wang, Zhimei Huang, Minshan Chen, Jinhua Huang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
    Jae Seung Lee, Hong Jun Choi, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Song-Ee Baek, Yong Eun Chung, Mi-Suk Park, Myeong-Jin Kim, Hyungjin Rhee, Seung Up Kim
    Gut and Liver.2020; 14(6): 765.     CrossRef
  • Comparison between hepatocellular carcinoma prognostic scores: A 10-year single-center experience and brief review of the current literature
    Michele Campigotto, Mauro Giuffrè, Anna Colombo, Alessia Visintin, Alessandro Aversano, Martina Budel, Flora Masutti, Cristiana Abazia, Lory Saveria Crocé
    World Journal of Hepatology.2020; 12(12): 1239.     CrossRef
  • Comparison of Partial Hepatectomy and Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Ismail Labgaa, Patrick Taffé, David Martin, Daniel Clerc, Myron Schwartz, Norihiro Kokudo, Alban Denys, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
    Liver Cancer.2020; 9(2): 138.     CrossRef
  • Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection
    Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim, Gianfranco D. Alpini
    PLOS ONE.2019; 14(4): e0214613.     CrossRef
  • Clinical Relevance of Reductive Hepatectomy for Barcelona Clinic Liver Cancer Stages B and C Advanced Hepatocellular Carcinoma: A Single‐Center Experience of 102 Patients
    Shohei Komatsu, Masahiro Kido, Motofumi Tanaka, Kaori Kuramitsu, ·Daisuke Tsugawa, Masahide Awazu, Hidetoshi Gon, Hirochika Toyama, Kimihiko Ueno, Takumi Fukumoto
    World Journal of Surgery.2019; 43(10): 2571.     CrossRef
  • Hepatocellular carcinoma staging systems: Hong Kong liver cancer vs Barcelona clinic liver cancer in a Western population
    Laura Bainy Rodrigues de Freitas, Larisse Longo, Deivid Santos, Ivana Grivicich, Mário Reis Álvares-da-Silva
    World Journal of Hepatology.2019; 11(9): 689.     CrossRef
  • Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis
    Lei Liang, Hao Xing, Han Zhang, Jianhong Zhong, Chao Li, Wan Yee Lau, Mengchao Wu, Feng Shen, Tian Yang
    HPB.2018; 20(2): 110.     CrossRef
  • Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms
    Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Juneyoung Lee, Hae Rim Kim, Yang Jae Yoo, Tae Suk Kim, Seong Hee Kang, Sang Jun Suh, Moon Kyung Joo, Young Kul Jung, Beom Jae Lee, Hyung Joon Yim, Jong Eun Yeon, Jae Seon Kim, Jong-Jae Park, Soon Ho Um, Young-Tae
    Gut and Liver.2018; 12(1): 94.     CrossRef
  • Chemoembolization related to good survival for selected patients with hepatocellular carcinoma invading segmental portal vein
    Jin Hyoung Kim, Ju Hyun Shim, Hyun‐Ki Yoon, Heung‐Kyu Ko, Jong Woo Kim, Dong Il Gwon
    Liver International.2018; 38(9): 1646.     CrossRef
  • Hepatic resection compared to chemoembolization in intermediate‐ to advanced‐stage hepatocellular carcinoma: A meta‐analysis of high‐quality studies
    Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
    Hepatology.2018; 68(3): 977.     CrossRef
  • Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma
    Biao Yang, Bo Zheng, MaoNan Yang, Zhu Zeng, FangYun Yang, Ji Pu, ChunLin Li, ZhengYin Liao
    Hepatology International.2018; 12(5): 417.     CrossRef
  • Impact of local tumor lesion treatments and preoperative indicators on the survival of patients with small hepatocellular carcinomas
    Yanyan Wei, Feng Dai, Yongxiang Yi, Wei Ye, Wei Zhao
    Oncology Letters.2018;[Epub]     CrossRef
  • Outcomes following liver resection for multinodular Barcelona Clinic Liver Cancer‑B hepatocellular carcinoma
    Satoshi Matsukuma, Kazuhiko Sakamoto, Yoshihiro Tokuhisa, Yukio Tokumitsu, Hiroto Matsui, Shinsuke Kanekiyo, Shinobu Tomochika, Michihisa Iida, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Hiroshi Wada, Shogo Kobayashi, Issei Saeki, Hidetoshi Eguchi, Masat
    Oncology Letters.2018;[Epub]     CrossRef
  • Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database
    Young‐Joo Jin, Jin‐Woo Lee
    Journal of Surgical Oncology.2017; 115(4): 407.     CrossRef
  • Validity of the Barcelona Clinic Liver Cancer and Hong Kong Liver Cancer staging systems for hepatocellular carcinoma in Singapore
    Li Kim E. Selby, Rosanna X. Y. Tay, Winston W. L. Woon, Jee Keem Low, Wang Bei, Vishalkumar G. Shelat, Tony C. Y. Pang, Sameer P. Junnarkar
    Journal of Hepato-Biliary-Pancreatic Sciences.2017; 24(3): 143.     CrossRef
  • Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B
    Yuri Cho, Dong Hyun Sinn, Su Jong Yu, Geum Youn Gwak, Ji Hoon Kim, Yang Jae Yoo, Dae Won Jun, Tae Yeob Kim, Hyo Young Lee, Eun Ju Cho, Jeong-Hoon Lee, Yoon Jun Kim, Jung-Hwan Yoon, Sheng-Nan Lu
    PLOS ONE.2016; 11(11): e0165722.     CrossRef
  • 15,181 View
  • 206 Download
  • 46 Web of Science
  • Crossref

Case Report

Benign liver tumors and cystic disease of liver

Intrahepatic bile duct adenoma in a patient with chronic hepatitis B accompanied by elevation of alpha-fetoprotein
Jem Ma Ahn, Yong-Han Paik, Jun Hee Lee, Ju Yeon Cho, Won Sohn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Clin Mol Hepatol 2015;21(4):393-397.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.393

A 51-year-old male patient with chronic hepatitis B was referred to our hospital due to a 1-cm liver nodule on ultrasonography. Alpha-fetoprotein (AFP) was slightly elevated. The nodule showed prolonged enhancement on dynamic liver magnetic resonance imaging and appeared as a hyperintensity on both diffusion-weighted and T2-weighted imaging. The nodule was followed up because it was small and typical findings of hepatocellular carcinoma (HCC) were not observed in the dynamic imaging investigations. However, liver contrast-enhanced ultrasonography performed 1 month later showed enhancement during the arterial phase and definite washout during the delayed phase. Also, AFP had increased to over 200 ng/mL even though AST and ALT were decreased after administering an antiviral agent. He was presumptively diagnosed as HCC and underwent liver segmentectomy. Microscopy findings of the specimen indicated bile duct adenoma. After resection, the follow-up AFP had decreased to within the normal range. This patient represents a case of bile duct adenoma with AFP elevation mimicking HCC on contrast-enhanced ultrasonography.

Citations

Citations to this article as recorded by  Crossref logo
  • Bile duct adenoma: imaging features and radiologic–pathologic correlation
    Ryoji Tatsumi, Shin Ichihara, Hirokazu Suii, Masakatsu Yamaguchi, Tomohiro Arakawa, Tomoaki Nakajima, Yasuaki Kuwata, Itaru Ozeki, Shuhei Hige, Joji Toyota, Yoshiyasu Karino
    Japanese Journal of Radiology.2020; 38(6): 561.     CrossRef
  • 14,144 View
  • 83 Download
  • 3 Web of Science
  • Crossref

Original Articles

Viral hepatitis

Static and dynamic prognostic factors for hepatitis-B-related acute-on-chronic liver failure
Jung Min Ha, Won Sohn, Ju Yeon Cho, Jeung Hui Pyo, Kyu Choi, Dong Hyun Sinn, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Chul Koh, Seung Woon Paik, Byung Chul Yoo, Yong-Han Paik
Clin Mol Hepatol 2015;21(3):232-241.
Published online September 30, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.3.232
Background/Aims

Hepatitis-B-related acute-on-chronic liver failure has a poor prognosis. However, the advent of potent oral antiviral agents means that some patients can now recover with medical treatment. We aimed to identify the prognostic factors for hepatitis-B-related acute-on-chronic liver failure including the initial as well as the dynamically changing clinical parameters during admission.

Methods

Sixty-seven patients were retrospectively enrolled from 2003 to 2012 at Samsung Medical Center. The patients were classified into three categories: Recovery group (n=23), Liver transplantation group (n=28), and Death group (n=16). The Liver transplantation and Death groups were combined into an Unfavorable prognosis group. We analyzed the prognostic factors including the Model for End-Stage Liver Disease (MELD) scores determined at 3-day intervals.

Results

A multivariable analysis showed that the unfavorable prognostic factors were a high initial MELD score (≥28) (odds ratio [OR] =6.64, p=0.015), moderate-to-severe ascites at admission (OR=6.71, P=0.012), and the aggravation of hepatic encephalopathy during hospitalization (≥grade III) (OR=15.41, P=0.013). Compared with the baseline level, significant reductions in the MELD scores were observed on the 7th day after admission in the Recovery group (P=0.016).

Conclusions

Dynamic changes in clinical parameters during admission are useful prognostic factors for hepatitis-B-related acute-on-chronic liver failure.

Citations

Citations to this article as recorded by  Crossref logo
  • Plasma galectin-3 can be considered as a non-invasive marker to predict the prognosis of ACLF patients with new typing
    Li Bai, Wang Lu, Qi Yang, Xiaoxuan Liu, Yu Chen, Zhongping Duan
    Scientific Reports.2025;[Epub]     CrossRef
  • Construction of a novel prognostic scoring model for HBV-ACLF liver failure based on dynamic data
    Qun Cai, Hao Wang, Mingyan Zhu, Yixin Xiao, Tingting Zhuo
    Scientific Reports.2024;[Epub]     CrossRef
  • PLT Counts as a Predictive Marker after Plasma Exchange in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure
    Xue Li, Hao Li, Yucui Zhu, Huaqian Xu, Shanhong Tang
    Journal of Clinical Medicine.2023; 12(3): 851.     CrossRef
  • Falla hepática aguda sobre crónica: análisis de una serie de casos y revisión de la literatura
    Jhon Edwar García-Rueda, Ricardo Londoño-García, Tomás Marín-Cuartas, Juan Esteban Hernández-Abaunza, Sebastián Osorio-Rico, Angélica María Bermúdez-Flórez, Juan Carlos Restrepo-Gutiérrez
    Hepatología.2022; : 72.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • A dynamic prediction model for prognosis of acute-on-chronic liver failure based on the trend of clinical indicators
    Zhenjun Yu, Yu Zhang, Yingying Cao, Manman Xu, Shaoli You, Yu Chen, Bing Zhu, Ming Kong, Fangjiao Song, Shaojie Xin, Zhongping Duan, Tao Han
    Scientific Reports.2021;[Epub]     CrossRef
  • Clinical Course and Outcome Patterns of Acute-on-chronic Liver Failure: A Multicenter Retrospective Cohort Study
    Man-Man Xu, Ming Kong, Peng-Fei Yu, Ying-Ying Cao, Fang Liu, Bing Zhu, Yi-Zhi Zhang, Wang Lu, Huai-Bin Zou, Bin-Wei Duan, Shao-Li You, Shao-Jie Xin, Tao Han, Zhong-Ping Duan, Yu Chen
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
  • A Dynamic Model for Predicting Outcome in Patients with HBV Related Acute-On-Chronic Liver Failure
    Wei Lin, Jing Zhang, Xiaohui Liu, Hongqun Liu, Jinqiu He, Ming Li, Shuqin Zhang, Hong Chen, Changqing Zhang, Wenfang Wu, Chenggang Jin, Samuel S. Lee, Zhongping Duan, Yuexin Zhang
    Annals of Hepatology.2018; 17(3): 392.     CrossRef
  • 11,557 View
  • 96 Download
  • 9 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

The comparison of esophageal variceal ligation plus propranolol versus propranolol alone for the primary prophylaxis of esophageal variceal bleeding
Dongmo Je, Yong-Han Paik, Geum-Youn Gwak, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo
Clin Mol Hepatol 2014;20(3):283-290.
Published online September 25, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.3.283
Background/Aims

To investigate the efficacy and longterm outcome of esophageal variceal ligation (EVL) plus propranolol in comparison with propranolol alone for the primary prophylaxis of esophageal variceal bleeding.

Methods

A total of 504 patients were retrospectively enrolled in this study. 330 patients were in propranolol group (Gr1) and 174 patients were in EVL plus propranolol group (Gr2). The endpoints of this study were esophageal variceal bleeding and mortality. Association analyses were performed to evaluate bleeding and mortality between Gr1 and Gr2.

Results

EVL was more applied in patients with high risk, such as large-sized varices (F2 or F3) or positive red color signs. Total 38 patients had bleeds, 32 in Gr1 and 6 in Gr2. The cumulative probability of bleeding at 120 months was 13% in Gr1 versus 4% in Gr2 (P=0.04). The predictive factors of variceal bleeding were red color signs (OR 2.962, P=0.007) and the method of propranolol plus EVL (OR 0.160, P=0.000). 20 patients died in Gr1 and 12 in Gr2. Mortality rates are similar in the two groups compared, 6.7% in Gr1 and 6.9% in Gr2. The cumulative probability of mortality at 120 months was not significantly different in the two groups (7% in Gr1, 12% in Gr2, P=0.798). The prognostic factors for mortality were age over 50 (OR 5.496, P=0.002), Child-Pugh class B (OR 3.979, P=0.001), and Child-Pugh class C (OR 10.861, P=0.000).

Conclusions

EVL plus propranolol is more effective than propranolol alone in the prevention of the first variceal bleeding in patients with liver cirrhosis.

Citations

Citations to this article as recorded by  Crossref logo
  • Analysis of risk factors for hospital-acquired pneumonia in schizophrenia
    Yu-hang Chen, Cong-ying Ren, Yu Liao
    Frontiers in Psychiatry.2024;[Epub]     CrossRef
  • Combined Pharmacological and Endoscopic Treatment for Worsening Gastroesophageal Varices in Patients with Cirrhosis
    Veronica Pepe, Paolo Angeli, Marco Di Pascoli
    Clinical and Experimental Gastroenterology.2022; Volume 15: 59.     CrossRef
  • Nonsurgical Secondary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients
    Liwei Jing, Qiumeng Zhang, Ziwei Chang, Hui Liu, Xuan Shi, Xingyu Li, Jing Wang, Yanbo Mo, Xiujing Zhang, Lizhuan Ma, Zhiting Li, Chao Zhang
    Journal of Clinical Gastroenterology.2021; 55(2): 159.     CrossRef
  • Influencing Factors of Hospital-Acquired Pneumonia Infection in the Middle-Aged and Elderly Patients With Schizophrenia
    Mi Yang, Qiwen Li, Chunzhi Wang, Li Li, Min Xu, Fei Yan, Wei Chen, Ying Wan
    Frontiers in Psychiatry.2021;[Epub]     CrossRef
  • Long-term outcome of endoscopic variceal band ligation of esophageal varices in patients with chronic liver disease
    Gautam Ray
    Indian Journal of Gastroenterology.2019; 38(1): 69.     CrossRef
  • Liver volume index predicts the risk of esophageal variceal hemorrhage in cirrhotic patients on propranolol prophylaxis
    Beom Hee Kim, Jung Wha Chung, Chung Seop Lee, Eun Sun Jang, Sook-Hyang Jeong, Nayoung Kim, Jin-Wook Kim
    The Korean Journal of Internal Medicine.2019; 34(6): 1233.     CrossRef
  • Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose‐response study
    R. Schwarzer, D. Kivaranovic, R. Paternostro, M. Mandorfer, T. Reiberger, M. Trauner, M. Peck‐Radosavljevic, A. Ferlitsch
    Alimentary Pharmacology & Therapeutics.2018; 47(8): 1162.     CrossRef
  • Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?
    Thomas Reiberger, Theresa Bucsics, Rafael Paternostro, Nikolaus Pfisterer, Florian Riedl, Mattias Mandorfer
    Current Hepatology Reports.2018; 17(4): 301.     CrossRef
  • Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
    Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon
    Gut and Liver.2017; 11(5): 702.     CrossRef
  • Changes in Cardiac Varices and Their Clinical Significance after Eradication of Esophageal Varices by Band Ligation
    Seung Woon Park, Yeon Seok Seo, Han Ah Lee, Sang Jung Park, Tae Hyung Kim, Jae Min Lee, Sang Jun Suh, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Young Kul Jung, Ji Hoon Kim, Hyonggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Hong Sik Lee, Hoon Jai Ch
    Canadian Journal of Gastroenterology and Hepatology.2016; 2016: 1.     CrossRef
  • 10,997 View
  • 93 Download
  • 10 Web of Science
  • Crossref

Editorial

Alcohol-related liver disease

Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?
Dong Hyun Sinn, Yong-Han Paik
Clin Mol Hepatol 2014;20(2):151-153.
Published online June 30, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.2.151
  • 9,179 View
  • 80 Download
Review
NADPH oxidase mediated oxidative stress in hepatic fibrogenesis
Yong-Han Paik, David A. Brenner
Korean J Hepatol 2011;17(4):251-257.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.251

NADPH oxidase (NOX) is a multicomponent enzyme complex that generates reactive oxygen species (ROS) in response to a wide range of stimuli. ROS is involved as key secondary messengers in numerous signaling pathways, and NADPH oxidases complex has been increasingly recognized as key elements of intracellular signaling of hepatic fibrogenesis. In the liver, NADPH oxidase is functionally expressed both in the phagocytic form and in the non-phagocytic form. The non-phagocytic NADPH oxidase complex is structurally and functionally similar to the phagocytic NADPH, resulting in reduction of molecular oxygen to generate superoxide. There are six homologous NOX proteins in the non-phagocytic forms of NADPH oxidase. An emerging concept is that both phagocytic and nonphagocytic NADPH oxidase components in hepatic stellate cells (HSCs) mediate hepatic fibrosis, suggesting its potential role as a pharmacological target for anti-fibrotic therapy. The molecular components and signaling pathways of various NADPH oxidase homologues that are critical for the fibrotic activity in HSCs need to be more clearly identified.

Citations

Citations to this article as recorded by  Crossref logo
  • Immune System and Hepatic Stellate Cells’ Crosstalk in Liver Fibrosis: Pathways and Therapeutic Potential
    Wahyu Widowati, Adilah Hafizha Nur Sabrina, Annisa Firdaus Sutendi, Fadhilah Haifa Zahiroh, Aris Muhamad Nurjamil, Teresa Liliana Wargasetia, Ita Margaretha Nainggolan, Rizal Azis, Elham Rismani, Massoud Vosough, Poorani Gurumallesh Prabu
    Journal of Immunology Research.2026;[Epub]     CrossRef
  • Beyond M1/M2: The role of reactive oxygen species in liver fibrosis and immune modulation
    Huilun Lu, Jie Huang, Ya-chao Wang, Eudald Casals, Gregori Casals, Muling Zeng
    Redox Biology.2025; 88: 103933.     CrossRef
  • Advancements in gene therapy approaches for atrial fibrillation: Targeted delivery, mechanistic insights and future prospects
    Roomana Khawajakhail, Rizwan Ullah Khan, Muhammad Umer Riaz Gondal, Hamza Khan Toru, Maria Malik, Arham Iqbal, Jahanzeb Malik, Maria Faraz, Muhammad Awais
    Current Problems in Cardiology.2024; 49(4): 102431.     CrossRef
  • Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression
    Natalia A. Osna, Irina Tikhanovich, Martí Ortega-Ribera, Sebastian Mueller, Chaowen Zheng, Johannes Mueller, Siyuan Li, Sadatsugu Sakane, Raquel Carvalho Gontijo Weber, Hyun Young Kim, Wonseok Lee, Souradipta Ganguly, Yusuke Kimura, Xiao Liu, Debanjan Dha
    Biomolecules.2024; 14(4): 404.     CrossRef
  • Insight into the regulation of the Nrf2 pathway in response to ascovirus infection in Spodoptera exigua
    Ruoheng Jin, Zhengkun Xiao, Madoka Nakai, Guo‐Hua Huang
    Pest Management Science.2023; 79(3): 1123.     CrossRef
  • Pre‐clinical evidence of a dual NADPH oxidase 1/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis
    Victor J. Thannickal, Karin Jandeleit‐Dahm, Cédric Szyndralewiez, Natalie J. Török
    Journal of Cellular and Molecular Medicine.2023; 27(4): 471.     CrossRef
  • Free Radicals and Oxidative Stress: Signaling Mechanisms, Redox Basis for Human Diseases, and Cell Cycle Regulation
    Idris Zubairu Sadiq
    Current Molecular Medicine.2023; 23(1): 13.     CrossRef
  • Chronic exposure to nonylphenol induces oxidative stress and liver damage in male zebrafish (Danio rerio): Mechanistic insight into cellular energy sensors, lipid accumulation and immune modulation
    Urmi Mukherjee, Anwesha Samanta, Subhasri Biswas, Soumyajyoti Ghosh, Sriparna Das, Sambuddha Banerjee, Sudipta Maitra
    Chemico-Biological Interactions.2022; 351: 109762.     CrossRef
  • Metformin Inhibits ROS Production by Human M2 Macrophages via the Activation of AMPK
    Rana M. Nassif, Elias Chalhoub, Pia Chedid, Margarita Hurtado-Nedelec, Elia Raya, Pham My-Chan Dang, Jean-Claude Marie, Jamel El-Benna
    Biomedicines.2022; 10(2): 319.     CrossRef
  • NADPH Oxidases Connecting Fatty Liver Disease, Insulin Resistance and Type 2 Diabetes: Current Knowledge and Therapeutic Outlook
    Alberto Nascè, Karim Gariani, François R. Jornayvaz, Ildiko Szanto
    Antioxidants.2022; 11(6): 1131.     CrossRef
  • The construction of preclinical evidence for the treatment of liver fibrosis with quercetin: A systematic review and meta‐analysis
    Xiaochuan Guo, Yuanyuan Li, Weizheng Wang, Luyao Wang, Sihan Hu, Xiaolin Xiao, Caiyu Hu, Yao Dai, Yiheng Zhang, Ziyu Li, Junlin Li, Xiao Ma, Jinhao Zeng
    Phytotherapy Research.2022; 36(10): 3774.     CrossRef
  • Alcoholic liver disease-from steatosis to cirrhosis - a biochemistry approach
    Ruxandra Cioarca-Nedelcu, Valeriu Atanasiu, Irina Stoian
    Journal of Medicine and Life.2021; 14(5): 594.     CrossRef
  • Role of cytoglobin, a novel radical scavenger, in stellate cell activation and hepatic fibrosis
    Le Thi Thanh Thuy, Hoang Hai, Norifumi Kawada
    Clinical and Molecular Hepatology.2020; 26(3): 280.     CrossRef
  • Long‐Term Measures of Dyslipidemia, Inflammation, and Oxidative Stress in Rats Fed a High‐Fat/High‐Fructose Diet
    Christine Feillet‐Coudray, Gilles Fouret, Claire Vigor, Béatrice Bonafos, Bernard Jover, Agnieszka Blachnio‐Zabielska, Jennifer Rieusset, François Casas, Sylvie Gaillet, Jean Francois Landrier, Thierry Durand, Charles Coudray
    Lipids.2019; 54(1): 81.     CrossRef
  • Gene therapy for atrial fibrillation - How close to clinical implementation?
    Amar Trivedi, Jacob Hoffman, Rishi Arora
    International Journal of Cardiology.2019; 296: 177.     CrossRef
  • Melatonin application in targeting oxidative‐induced liver injuries: A review
    Keywan Mortezaee, Neda Khanlarkhani
    Journal of Cellular Physiology.2018; 233(5): 4015.     CrossRef
  • Inhibition of autophagy reverses alcohol-induced hepatic stellate cells activation through activation of Nrf2-Keap1-ARE signaling pathway
    Zheng-Yuan Xie, Zhi-Hua Xiao, Fen-Fen Wang
    Biochimie.2018; 147: 55.     CrossRef
  • Hepatoprotective effects of curcumin in rats after bile duct ligation via downregulation of Rac1 and NOX1
    Zohreh-al-sadat Ghoreshi, Razieh Kabirifar, Fatemeh Safari, Alireza Karimollah, Ali Moradi, Ebrahim Eskandari-Nasab
    Nutrition.2017; 36: 72.     CrossRef
  • The effects of urotensin II on migration and invasion are mediated by NADPH oxidase-derived reactive oxygen species through the c-Jun N-terminal kinase pathway in human hepatoma cells
    Ying-ying Li, Zheng-ming Shi, Xiao-tong Yu, Ping Feng, Xue-Jiang Wang
    Peptides.2017; 88: 106.     CrossRef
  • Baccharis trimerainhibits reactive oxygen species production through PKC and down-regulation p47phoxphosphorylation of NADPH oxidase in SK Hep-1 cells
    Glaucy Rodrigues de Araújo, Ana Carolina Silveira Rabelo, Janaína Serenato Meira, Joamyr Victor Rossoni-Júnior, William de Castro-Borges, Renata Guerra-Sá, Maurício Azevedo Batista, Denise da Silveira-Lemos, Gustavo Henrique Bianco de Souza, Geraldo Célio
    Experimental Biology and Medicine.2017; 242(3): 333.     CrossRef
  • Quercetin protects liver injury induced by bile duct ligation via attenuation of Rac1 and NADPH oxidase1 expression in rats
    Razieh Kabirifar, Zohreh-al-sadat Ghoreshi, Fatemeh Safari, Alireza Karimollah, Ali Moradi, Ebrahim Eskandari-nasab
    Hepatobiliary & Pancreatic Diseases International.2017; 16(1): 88.     CrossRef
  • Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice
    Takafumi Yoshida, Jun Akiba, Takanori Matsui, Kazuo Nakamura, Takao Hisamoto, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Hideki Iwamoto, Toru Nakamura, Hironori Koga, Sho-ichi Yamagishi, Takuji Torimura
    Digestive Diseases and Sciences.2017; 62(6): 1527.     CrossRef
  • Hybrid Nitric Oxide Donor and its Carrier for the Treatment of Peripheral Arterial Diseases
    Duong Q. Le, Aneetta E. Kuriakose, Dat X. Nguyen, Kytai T. Nguyen, Suchismita Acharya
    Scientific Reports.2017;[Epub]     CrossRef
  • Caveolin 1-related autophagy initiated by aldosterone-induced oxidation promotes liver sinusoidal endothelial cells defenestration
    Xiaoying Luo, Dan Wang, Xuan Luo, Xintao Zhu, Guozhen Wang, Zuowei Ning, Yang Li, Xiaoxin Ma, Renqiang Yang, Siyi Jin, Yun Huang, Ying Meng, Xu Li
    Redox Biology.2017; 13: 508.     CrossRef
  • Ursolic acid suppresses TGF-β1-induced quiescent HSC activation and transformation by inhibiting NADPH oxidase expression and Hedgehog signaling
    Shan-Shan Yu, Biao Chen, Chen-Kai Huang, Juan-Juan Zhou, Xin Huang, An-Jiang Wang, Bi-Min Li, Wen-Hua He, Xuan Zhu
    Experimental and Therapeutic Medicine.2017; 14(4): 3577.     CrossRef
  • Isoniazid Induced Toxicities and Idiosyncratic Responses in Male Albino Wistar Rats
    Solomon E. Owumi, Michael A. Gbadegesin, Fisayo A. Olotu, Oyeronke A. Odunola
    Journal of Cancer Research Updates.2017;[Epub]     CrossRef
  • Role of redoximiRs in fibrogenesis
    Marta Fierro-Fernández, Verónica Miguel, Santiago Lamas
    Redox Biology.2016; 7: 58.     CrossRef
  • Is Liver Enzyme Release Really Associated with Cell Necrosis Induced by Oxidant Stress?
    Martha Lucinda Contreras-Zentella, Rolando Hernández-Muñoz, Karina R. Gordillo
    Oxidative Medicine and Cellular Longevity.2016;[Epub]     CrossRef
  • Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice
    In Hee Kim, Jun Xu, Xiao Liu, Yukinori Koyama, Hsiao-Yen Ma, Karin Diggle, Young-Hyun You, Jan M. Schilling, Dilip Jeste, Kumar Sharma, David A. Brenner, Tatiana Kisseleva
    AGE.2016; 38(4): 291.     CrossRef
  • Effects on intestinal microbiota and immune genes of Solea senegalensis after suspension of the administration of Shewanella putrefaciens Pdp11
    Sara Vidal, Silvana Teresa Tapia-Paniagua, Jesús Miguel Moriñigo, Carmen Lobo, Inés García de la Banda, María del Carmen Balebona, Miguel Ángel Moriñigo
    Fish & Shellfish Immunology.2016; 58: 274.     CrossRef
  • Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation
    Diptadip Dattaroy, Ratanesh Kumar Seth, Suvarthi Das, Firas Alhasson, Varun Chandrashekaran, Gregory Michelotti, Daping Fan, Mitzi Nagarkatti, Prakash Nagarkatti, Anna Mae Diehl, Saurabh Chatterjee
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2016; 310(7): G510.     CrossRef
  • Dietary administration of the probiotic SpPdp11: Effects on the intestinal microbiota and immune-related gene expression of farmed Solea senegalensis treated with oxytetracycline
    S.T. Tapia-Paniagua, S. Vidal, C. Lobo, I. García de la Banda, M.A. Esteban, M.C. Balebona, M.A. Moriñigo
    Fish & Shellfish Immunology.2015; 46(2): 449.     CrossRef
  • Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis
    Diptadip Dattaroy, Sahar Pourhoseini, Suvarthi Das, Firas Alhasson, Ratanesh Kumar Seth, Mitzi Nagarkatti, Gregory A. Michelotti, Anna Mae Diehl, Saurabh Chatterjee
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2015; 308(4): G298.     CrossRef
  • Exploring the Molecular Basis for Selective Binding of Homoserine Dehydrogenase from Mycobacterium leprae TN toward Inhibitors: A Virtual Screening Study
    Dongling Zhan, Dongmei Wang, Weihong Min, Weiwei Han
    International Journal of Molecular Sciences.2014; 15(2): 1826.     CrossRef
  • Expression profiles of fetal membrane nicotinamide adenine dinucleotide phosphate oxidases (NOX) 2 and 3 differentiates spontaneous preterm birth and pPROM pathophysiologies
    J. Polettini, M.G. Silva, M. Kacerovsky, T.A. Syed, G. Saade, R. Menon
    Placenta.2014; 35(3): 188.     CrossRef
  • Andrographis paniculata Leaf Extract Prevents Thioacetamide-Induced Liver Cirrhosis in Rats
    Daleya Abdulaziz Bardi, Mohammed Farouq Halabi, Pouya Hassandarvish, Elham Rouhollahi, Mohammadjavad Paydar, Soheil Zorofchian Moghadamtousi, Nahla Saeed Al-Wajeeh, Abdulwali Ablat, Nor Azizan Abdullah, Mahmood Ameen Abdulla, Aamir Ahmad
    PLoS ONE.2014; 9(10): e109424.     CrossRef
  • Hypercholesterolemic diet induces hepatic steatosis and alterations in mRNA expression of NADPH oxidase in rat livers
    Isabel Cristina Mallosto Emerich de Abreu, Joyce Ferreira da Costa Guerra, Renata Rebeca Pereira, Maísa Silva, Wanderson Geraldo de Lima, Marcelo Eustáquio Silva, Maria Lúcia Pedrosa
    Arquivos Brasileiros de Endocrinologia & Metabologia.2014; 58(3): 251.     CrossRef
  • Hepatocyte Growth Factor Protects Against Isoniazid/Rifampicin-Induced Oxidative Liver Damage
    Cristina Enriquez-Cortina, Maylin Almonte-Becerril, Denise Clavijo-Cornejo, Mayrel Palestino-Domínguez, Oscar Bello-Monroy, Natalia Nuño, Anayelly López, Leticia Bucio, Verónica Souza, Rogelio Hernández-Pando, Linda Muñoz, María Concepción Gutiérrez-Ruiz,
    Toxicological Sciences.2013; 135(1): 26.     CrossRef
  • Expression and Function of Methylthioadenosine Phosphorylase in Chronic Liver Disease
    Barbara Czech, Katja Dettmer, Daniela Valletta, Michael Saugspier, Andreas Koch, Axel P. Stevens, Wolfgang E. Thasler, Martina Müller, Peter J. Oefner, Anja-Katrin Bosserhoff, Claus Hellerbrand, Matias A Avila
    PLoS ONE.2013; 8(12): e80703.     CrossRef
  • Docosahexaenoic Acid Attenuates Hepatic Inflammation, Oxidative Stress, and Fibrosis without Decreasing Hepatosteatosis in a Ldlr Mouse Model of Western Diet-Induced Nonalcoholic Steatohepatitis
    Christopher M. Depner, Kenneth A. Philbrick, Donald B. Jump
    The Journal of Nutrition.2013; 143(3): 315.     CrossRef
  • Diagnostic accuracy of biomarkers measured in the hepatic vein and peripheral vein in the prediction of advanced fibrosis in patients with chronic viral hepatitis
    Ki Tae Suk, Dong Joon Kim, Chang Hoon Kim, Seung Ha Park, Jae Youn Cheong, Sung Won Cho, Jong Young Choi, Kwang Hyub Han, Ho Taik Sung, So Hyung Hong, Dae Yong Kim, Jai Hoon Yoon, Yeon Soo Kim, Gwang Ho Baik, Jin Bong Kim
    Clinical Biochemistry.2012; 45(13-14): 1075.     CrossRef
  • Mesenchymal stem cells restore CCl4‐induced liver injury by an antioxidative process
    Kyung‐Ah Cho, So‐Youn Woo, Ju‐Young Seoh, Ho‐Seong Han, Kyung‐Ha Ryu
    Cell Biology International.2012; 36(12): 1267.     CrossRef
  • 12,144 View
  • 79 Download
  • Crossref